GENE NAME,PARAGRAPH 1 (Gene Association),PARAGRAPH 2 (Gene Condition),PARAGRAPH 3 (Gene Condition Overflow),A2M CURVE,A2M REQUESTS,HideA2MCharts,SQL,Concatenated
Gene,,,,,,,,Concatenated
ABRAXAS1,"The ABRAXAS1 gene, formerly known as FAM175A, currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22357538).",,,NO,,,"('ABRAXAS1', 'The ABRAXAS1 gene, formerly known as FAM175A, currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22357538).', '', '', '1', NULL),","The ABRAXAS1 gene, formerly known as FAM175A, currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22357538)."
AIP,The AIP gene is associated with autosomal dominant predisposition to familial isolated pituitary adenoma (FIPA) (MedGen UID: 489979).,"FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299).",,NO,,,"('AIP', 'The AIP gene is associated with autosomal dominant predisposition to familial isolated pituitary adenoma (FIPA) (MedGen UID: 489979).', 'FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299).', '', '0', NULL),","The AIP gene is associated with autosomal dominant predisposition to familial isolated pituitary adenoma (FIPA) (MedGen UID: 489979).  FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299)."
ALK,The ALK gene is associated with autosomal dominant predisposition to neuroblastoma (MedGen UID: 414083).,"Neuroblastoma is a tumor affecting developing nerve cells, and therefore most often affects infants and young children (PMID: 18242317). Studies have identified pathogenic ALK variants in families exhibiting a predisposition to neuroblastoma (PMID: 18724359, 18923523, 22071890) with incomplete penetrance (PMID: 18923503).",,NO,,,"('ALK', 'The ALK gene is associated with autosomal dominant predisposition to neuroblastoma (MedGen UID: 414083).', 'Neuroblastoma is a tumor affecting developing nerve cells, and therefore most often affects infants and young children (PMID: 18242317). Studies have identified pathogenic ALK variants in families exhibiting a predisposition to neuroblastoma (PMID: 18724359, 18923523, 22071890) with incomplete penetrance (PMID: 18923503).', '', '0', NULL),","The ALK gene is associated with autosomal dominant predisposition to neuroblastoma (MedGen UID: 414083).  Neuroblastoma is a tumor affecting developing nerve cells, and therefore most often affects infants and young children (PMID: 18242317). Studies have identified pathogenic ALK variants in families exhibiting a predisposition to neuroblastoma (PMID: 18724359, 18923523, 22071890) with incomplete penetrance (PMID: 18923503)."
ANKRD26,"The ANKRD26 gene is associated with isolated, non-syndromic autosomal dominant thrombocytopenia (MedGen UID: 349976). Additionally, the ANKRD26 gene has preliminary evidence supporting a correlation with autosomal dominant familial leukemia (PMID: 24628296, 24030261).","Inherited thrombocytopenia is associated with mild-to-severe tendency to bruising and bleeding due to a decreased platelet count (PMID: 21211618). Laboratory studies reveal increased total white blood count and plasma thrombopoietin (TPO) (PMID: 24628296, 21211618). Bone marrow examination reveals dysmegakaryopoiesis, suggesting defective platelet production (PMID: 21211618, 26175287). Some studies have identified a pathogenic ANKRD26 variant in individuals with increased susceptibility to myeloid malignancies (PMID: 24030261, 24628296).",,NO,,,"('ANKRD26', 'The ANKRD26 gene is associated with isolated, non-syndromic autosomal dominant thrombocytopenia (MedGen UID: 349976). Additionally, the ANKRD26 gene has preliminary evidence supporting a correlation with autosomal dominant familial leukemia (PMID: 24628296, 24030261).', 'Inherited thrombocytopenia is associated with mild-to-severe tendency to bruising and bleeding due to a decreased platelet count (PMID: 21211618). Laboratory studies reveal increased total white blood count and plasma thrombopoietin (TPO) (PMID: 24628296, 21211618). Bone marrow examination reveals dysmegakaryopoiesis, suggesting defective platelet production (PMID: 21211618, 26175287). Some studies have identified a pathogenic ANKRD26 variant in individuals with increased susceptibility to myeloid malignancies (PMID: 24030261, 24628296).', '', '0', NULL),","The ANKRD26 gene is associated with isolated, non-syndromic autosomal dominant thrombocytopenia (MedGen UID: 349976). Additionally, the ANKRD26 gene has preliminary evidence supporting a correlation with autosomal dominant familial leukemia (PMID: 24628296, 24030261).  Inherited thrombocytopenia is associated with mild-to-severe tendency to bruising and bleeding due to a decreased platelet count (PMID: 21211618). Laboratory studies reveal increased total white blood count and plasma thrombopoietin (TPO) (PMID: 24628296, 21211618). Bone marrow examination reveals dysmegakaryopoiesis, suggesting defective platelet production (PMID: 21211618, 26175287). Some studies have identified a pathogenic ANKRD26 variant in individuals with increased susceptibility to myeloid malignancies (PMID: 24030261, 24628296)."
APC - Classic FAP,"The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).","FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).","Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).",NO,,,"('APC - Classic FAP', 'The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                ', 'FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5'' and 3'' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).', 'Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).', '0', NULL),","The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414)."
APC - Attenuated FAP,"The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).","FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).","Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).",NO,,,"('APC - Attenuated FAP', 'The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                ', 'FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5'' and 3'' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).', 'Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).', '0', NULL),","The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414)."
APC - I1307K Variant,"The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).","FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).","Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).",NO,,,"('APC - I1307K Variant', 'The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                ', 'FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5'' and 3'' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).', 'Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).', '0', NULL),","The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414)."
APC - GAPPS,"The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).","FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).","Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).",NO,,,"('APC - GAPPS', 'The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                ', 'FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5'' and 3'' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).', 'Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).', '0', NULL),","The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414)."
ARMC5,The ARMC5 gene is associated with autosomal dominant primary bilateral macronodular adrenal hyperplasia (PBMAH) (MedGen UID: 863240).,"Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a condition that primarily affects the adrenal glands. The adrenal glands are glands on top of the kidneys that produce hormones regulating many essential functions in the body. PBMAH is a condition that can cause lumps (nodules) to form in the adrenal glands leading them to enlarge and produce too much of a certain hormone (cortisol). Increased cortisol can result in weight gain, high blood pressure (hypertension), diabetes, fatigue and bone loss. When symptoms of PBMAH are present, they usually begin in middle age. However, some with PBMAH may not have any obvious symptoms (incomplete penetrance). Specific laboratory tests and imaging are typically used to diagnose PBMAH. A dexamethasone suppression test measures the response of the adrenal glands to the hormone ACTH (adrenocorticotropic hormone); affected individuals often have elevated cortisol levels in blood and urine as well as low levels of ACTH in blood following this test. Imaging often shows large, nodular adrenal glands. Treatment for severe cases may include the surgical removal of one or both adrenal glands. Otherwise treatment is supportive and focused on managing the individual's symptoms.",,NO,,,"('ARMC5', 'The ARMC5 gene is associated with autosomal dominant primary bilateral macronodular adrenal hyperplasia (PBMAH) (MedGen UID: 863240).', 'Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a condition that primarily affects the adrenal glands. The adrenal glands are glands on top of the kidneys that produce hormones regulating many essential functions in the body. PBMAH is a condition that can cause lumps (nodules) to form in the adrenal glands leading them to enlarge and produce too much of a certain hormone (cortisol). Increased cortisol can result in weight gain, high blood pressure (hypertension), diabetes, fatigue and bone loss. When symptoms of PBMAH are present, they usually begin in middle age. However, some with PBMAH may not have any obvious symptoms (incomplete penetrance). Specific laboratory tests and imaging are typically used to diagnose PBMAH. A dexamethasone suppression test measures the response of the adrenal glands to the hormone ACTH (adrenocorticotropic hormone); affected individuals often have elevated cortisol levels in blood and urine as well as low levels of ACTH in blood following this test. Imaging often shows large, nodular adrenal glands. Treatment for severe cases may include the surgical removal of one or both adrenal glands. Otherwise treatment is supportive and focused on managing the individual''s symptoms.', '', '0', NULL),","The ARMC5 gene is associated with autosomal dominant primary bilateral macronodular adrenal hyperplasia (PBMAH) (MedGen UID: 863240).  Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a condition that primarily affects the adrenal glands. The adrenal glands are glands on top of the kidneys that produce hormones regulating many essential functions in the body. PBMAH is a condition that can cause lumps (nodules) to form in the adrenal glands leading them to enlarge and produce too much of a certain hormone (cortisol). Increased cortisol can result in weight gain, high blood pressure (hypertension), diabetes, fatigue and bone loss. When symptoms of PBMAH are present, they usually begin in middle age. However, some with PBMAH may not have any obvious symptoms (incomplete penetrance). Specific laboratory tests and imaging are typically used to diagnose PBMAH. A dexamethasone suppression test measures the response of the adrenal glands to the hormone ACTH (adrenocorticotropic hormone); affected individuals often have elevated cortisol levels in blood and urine as well as low levels of ACTH in blood following this test. Imaging often shows large, nodular adrenal glands. Treatment for severe cases may include the surgical removal of one or both adrenal glands. Otherwise treatment is supportive and focused on managing the individual's symptoms."
ASXL1,"The ASXL1 gene is associated with autosomal dominant Bohring-Opitz syndrome (BOS), which is also known as C-like syndrome (MedGen UID: 208678).","BOS is characterized by multiple congenital malformations, intrauterine growth restriction, feeding difficulties, severe intellectual disability, and distinctive facial features (PMID: 16691589). Associated congenital malformations include palate abnormalities, microcephaly, trigonocephaly, and structural brain anomalies. Reported craniofacial features include exophthalmos, upslanting palpebral fissures, depressed and wide nasal bridge, hypertelorism, low-set posteriorly rotated ears, and facial nevus flammeus. A characteristic limb posture of flexion of the elbows, wrists, and metacarpophalangeal joints has been described. Other features including hypertrichosis, myopia, seizures, central obesity, Wilms tumor, and cardiac, ophthalmologic and gastrointestinal anomalies have been described (PMID: 21706002, 25921057, 26364555). For a review of clinical management for BOS, please refer to Russell et al., 2015 (PMID: 25921057).",,NO,,,"('ASXL1', 'The ASXL1 gene is associated with autosomal dominant Bohring-Opitz syndrome (BOS), which is also known as C-like syndrome (MedGen UID: 208678).', 'BOS is characterized by multiple congenital malformations, intrauterine growth restriction, feeding difficulties, severe intellectual disability, and distinctive facial features (PMID: 16691589). Associated congenital malformations include palate abnormalities, microcephaly, trigonocephaly, and structural brain anomalies. Reported craniofacial features include exophthalmos, upslanting palpebral fissures, depressed and wide nasal bridge, hypertelorism, low-set posteriorly rotated ears, and facial nevus flammeus. A characteristic limb posture of flexion of the elbows, wrists, and metacarpophalangeal joints has been described. Other features including hypertrichosis, myopia, seizures, central obesity, Wilms tumor, and cardiac, ophthalmologic and gastrointestinal anomalies have been described (PMID: 21706002, 25921057, 26364555). For a review of clinical management for BOS, please refer to Russell et al., 2015 (PMID: 25921057).', '', '0', NULL),","The ASXL1 gene is associated with autosomal dominant Bohring-Opitz syndrome (BOS), which is also known as C-like syndrome (MedGen UID: 208678).  BOS is characterized by multiple congenital malformations, intrauterine growth restriction, feeding difficulties, severe intellectual disability, and distinctive facial features (PMID: 16691589). Associated congenital malformations include palate abnormalities, microcephaly, trigonocephaly, and structural brain anomalies. Reported craniofacial features include exophthalmos, upslanting palpebral fissures, depressed and wide nasal bridge, hypertelorism, low-set posteriorly rotated ears, and facial nevus flammeus. A characteristic limb posture of flexion of the elbows, wrists, and metacarpophalangeal joints has been described. Other features including hypertrichosis, myopia, seizures, central obesity, Wilms tumor, and cardiac, ophthalmologic and gastrointestinal anomalies have been described (PMID: 21706002, 25921057, 26364555). For a review of clinical management for BOS, please refer to Russell et al., 2015 (PMID: 25921057)."
ATM,"The ATM gene is associated with autosomal dominant predisposition to breast, ovarian, pancreatic (PMID: 26483394, 28888541, 30733081) and prostate cancer (PMID: 27989354, 28657667). ATM is also associated with autosomal recessive ataxia-telangiectasia (A-T) (MedGen UID: 439). Additionally, there is evidence suggesting ATM is associated with autosomal dominant predisposition to gastric (PMID: 26182300) and colon cancer (PMID: 30862463). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","The lifetime risk of breast cancer in females with one pathogenic ATM variant is approximately 21-33% (PMID: 30733081, 33471974, 27112364). There is also an increased risk of ovarian, pancreatic and prostate cancer; however, lifetime risks are not established (PMID: 30733081, 28767289, 27989354).","A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results using specimens containing leukocytes may not distinguish between germline and acquired variants and additional testing may be appropriate.",YES,Hide Prostate,"[""Prostate""]","('ATM', 'The ATM gene is associated with autosomal dominant predisposition to breast, ovarian, pancreatic (PMID: 26483394, 28888541, 30733081) and prostate cancer (PMID: 27989354, 28657667). ATM is also associated with autosomal recessive ataxia-telangiectasia (A-T) (MedGen UID: 439). Additionally, there is evidence suggesting ATM is associated with autosomal dominant predisposition to gastric (PMID: 26182300) and colon cancer (PMID: 30862463). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'The lifetime risk of breast cancer in females with one pathogenic ATM variant is approximately 21-33% (PMID: 30733081, 33471974, 27112364). There is also an increased risk of ovarian, pancreatic and prostate cancer; however, lifetime risks are not established (PMID: 30733081, 28767289, 27989354).', 'A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results using specimens containing leukocytes may not distinguish between germline and acquired variants and additional testing may be appropriate.', '0', '[""Prostate""]'),","The ATM gene is associated with autosomal dominant predisposition to breast, ovarian, pancreatic (PMID: 26483394, 28888541, 30733081) and prostate cancer (PMID: 27989354, 28657667). ATM is also associated with autosomal recessive ataxia-telangiectasia (A-T) (MedGen UID: 439). Additionally, there is evidence suggesting ATM is associated with autosomal dominant predisposition to gastric (PMID: 26182300) and colon cancer (PMID: 30862463). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with one pathogenic ATM variant is approximately 21-33% (PMID: 30733081, 33471974, 27112364). There is also an increased risk of ovarian, pancreatic and prostate cancer; however, lifetime risks are not established (PMID: 30733081, 28767289, 27989354).  A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results using specimens containing leukocytes may not distinguish between germline and acquired variants and additional testing may be appropriate."
ATR,"The ATR gene is associated with autosomal recessive Seckel syndrome 1 (MedGen UID: 830512). There is also evidence suggesting ATR is associated with autosomal dominant predisposition to prostate (PMID: 27433846) and oropharyngeal cancer (PMID: 22341969). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","Seckel syndrome is characterized by microcephaly and absence of visceral malformations (PMID: 20301772). Microcephaly may become apparent in the second trimester of gestation, is typically non-progressive, and is associated with varying degrees of cognitive impairment and developmental delay (PMID: 25951892, 26050940). Severe pre- and post-natal growth failure is common (PMID: 25951892, 20301772). Structural brain malformations, craniosynostosis, seizures and pancytopenia have also been described (PMID: 26050940, 20301772).",,NO,,,"('ATR', 'The ATR gene is associated with autosomal recessive Seckel syndrome 1 (MedGen UID: 830512). There is also evidence suggesting ATR is associated with autosomal dominant predisposition to prostate (PMID: 27433846) and oropharyngeal cancer (PMID: 22341969). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                        ', 'Seckel syndrome is characterized by microcephaly and absence of visceral malformations (PMID: 20301772). Microcephaly may become apparent in the second trimester of gestation, is typically non-progressive, and is associated with varying degrees of cognitive impairment and developmental delay (PMID: 25951892, 26050940). Severe pre- and post-natal growth failure is common (PMID: 25951892, 20301772). Structural brain malformations, craniosynostosis, seizures and pancytopenia have also been described (PMID: 26050940, 20301772).                                                        ', '', '1', NULL),","The ATR gene is associated with autosomal recessive Seckel syndrome 1 (MedGen UID: 830512). There is also evidence suggesting ATR is associated with autosomal dominant predisposition to prostate (PMID: 27433846) and oropharyngeal cancer (PMID: 22341969). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                          Seckel syndrome is characterized by microcephaly and absence of visceral malformations (PMID: 20301772). Microcephaly may become apparent in the second trimester of gestation, is typically non-progressive, and is associated with varying degrees of cognitive impairment and developmental delay (PMID: 25951892, 26050940). Severe pre- and post-natal growth failure is common (PMID: 25951892, 20301772). Structural brain malformations, craniosynostosis, seizures and pancytopenia have also been described (PMID: 26050940, 20301772)."
AXIN2,The AXIN2 gene is associated with autosomal dominant oligodontia-colorectal cancer syndrome (MedGen UID: 324868).,"Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677).",,NO,,,"('AXIN2', 'The AXIN2 gene is associated with autosomal dominant oligodontia-colorectal cancer syndrome (MedGen UID: 324868).								', 'Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677).', '', '0', NULL),","The AXIN2 gene is associated with autosomal dominant oligodontia-colorectal cancer syndrome (MedGen UID: 324868).								  Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677)."
BAP1,"The BAP1 gene is associated with autosomal dominant BAP1 tumor predisposition syndrome (MedGen UID: 482122). There is also evidence suggesting BAP1 is associated with autosomal dominant predisposition to meningioma (PMID: 30517737). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012).",,NO,,,"('BAP1', 'The BAP1 gene is associated with autosomal dominant BAP1 tumor predisposition syndrome (MedGen UID: 482122). There is also evidence suggesting BAP1 is associated with autosomal dominant predisposition to meningioma (PMID: 30517737). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012).', '', '0', NULL),","The BAP1 gene is associated with autosomal dominant BAP1 tumor predisposition syndrome (MedGen UID: 482122). There is also evidence suggesting BAP1 is associated with autosomal dominant predisposition to meningioma (PMID: 30517737). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012)."
BARD1,"The BARD1 gene is associated with autosomal dominant predisposition to breast cancer (MedGen UID: 87542). Elevated risks for ovarian cancer and neuroblastoma have also been suggested (PMID: 22006311, 23334666). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.","Females with a pathogenic BARD1 variant have an increased risk of breast cancer; the lifetime risk is 22-29% (PMID: 28418444, 32091585, Kurian et al. 2017).",,YES,,,"('BARD1', 'The BARD1 gene is associated with autosomal dominant predisposition to breast cancer (MedGen UID: 87542). Elevated risks for ovarian cancer and neuroblastoma have also been suggested (PMID: 22006311, 23334666). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.', 'Females with a pathogenic BARD1 variant have an increased risk of breast cancer; the lifetime risk is 22-29% (PMID: 28418444, 32091585, Kurian et al. 2017). ', '', '0', NULL),","The BARD1 gene is associated with autosomal dominant predisposition to breast cancer (MedGen UID: 87542). Elevated risks for ovarian cancer and neuroblastoma have also been suggested (PMID: 22006311, 23334666). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  Females with a pathogenic BARD1 variant have an increased risk of breast cancer; the lifetime risk is 22-29% (PMID: 28418444, 32091585, Kurian et al. 2017)."
BLM,"The BLM gene is associated with autosomal recessive Bloom syndrome (MedGen UID: 2685). Studies have also suggested BLM may be associated with autosomal dominant predisposition to colorectal cancer (PMID: 12242432, 26358404). The evidence, however, is preliminary and insufficient to make a determination regarding this relationship.","Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175).",,NO,,,"('BLM', 'The BLM gene is associated with autosomal recessive Bloom syndrome (MedGen UID: 2685). Studies have also suggested BLM may be associated with autosomal dominant predisposition to colorectal cancer (PMID: 12242432, 26358404). The evidence, however, is preliminary and insufficient to make a determination regarding this relationship.                                                                        ', 'Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175).', '', '1', NULL),","The BLM gene is associated with autosomal recessive Bloom syndrome (MedGen UID: 2685). Studies have also suggested BLM may be associated with autosomal dominant predisposition to colorectal cancer (PMID: 12242432, 26358404). The evidence, however, is preliminary and insufficient to make a determination regarding this relationship.                                                                          Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175)."
BMPR1A,The BMPR1A gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518).,"JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. There is an increased risk of developing colon cancer and stomach cancer (PMID: 20859198, 2705469). The risk of colon cancer is 40-50% (PMID: 22846733, 9869523) and the risk of gastric cancer is up to 21% (PMID: 12221036).",,NO,,,"('BMPR1A', 'The BMPR1A gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518).', 'JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. There is an increased risk of developing colon cancer and stomach cancer (PMID: 20859198, 2705469). The risk of colon cancer is 40-50% (PMID: 22846733, 9869523) and the risk of gastric cancer is up to 21% (PMID: 12221036). ', '', '0', NULL),","The BMPR1A gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518).  JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. There is an increased risk of developing colon cancer and stomach cancer (PMID: 20859198, 2705469). The risk of colon cancer is 40-50% (PMID: 22846733, 9869523) and the risk of gastric cancer is up to 21% (PMID: 12221036)."
BRCA1,"The BRCA1 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793). Additionally, the BRCA1 gene has preliminary evidence supporting a correlation with autosomal recessive Fanconi anemia (MedGen UID: 1632414).","HBOC due to a clinically significant change in the BRCA1 gene is characterized by an increased risk of breast cancer (in both females and males), ovarian cancer, prostate cancer, pancreatic cancer and possibly melanoma when compared to individuals in the general population. The lifetime risk of breast cancer for females with a positive BRCA1 variant is 53-78% (PMID: 32676552, 33471974) and the chance of developing breast cancer again in their other breast (contralateral breast cancer) within 10 years after the first diagnosis is estimated to be 20-42% (PMID: 26700119). The lifetime risk to develop ovarian or fallopian tube cancer is 44-65% (PMID: 32676552). Males with HBOC due to a change in the BRCA1 gene have a 1-2% lifetime risk of developing breast cancer (PMID: 18042939) and an increased risk of prostate cancer, although specific lifetime risks are not clear (PMID: 30900310). Both males and females with a positive BRCA1 variant have a 3-4% lifetime risk of pancreatic cancer (PMID: 29922827, 27306910).",,YES,,,"('BRCA1', 'The BRCA1 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793). Additionally, the BRCA1 gene has preliminary evidence supporting a correlation with autosomal recessive Fanconi anemia (MedGen UID: 1632414).', 'HBOC due to a clinically significant change in the BRCA1 gene is characterized by an increased risk of breast cancer (in both females and males), ovarian cancer, prostate cancer, pancreatic cancer and possibly melanoma when compared to individuals in the general population. The lifetime risk of breast cancer for females with a positive BRCA1 variant is 53-78% (PMID: 32676552, 33471974) and the chance of developing breast cancer again in their other breast (contralateral breast cancer) within 10 years after the first diagnosis is estimated to be 20-42% (PMID: 26700119). The lifetime risk to develop ovarian or fallopian tube cancer is 44-65% (PMID: 32676552). Males with HBOC due to a change in the BRCA1 gene have a 1-2% lifetime risk of developing breast cancer (PMID: 18042939) and an increased risk of prostate cancer, although specific lifetime risks are not clear (PMID: 30900310). Both males and females with a positive BRCA1 variant have a 3-4% lifetime risk of pancreatic cancer (PMID: 29922827, 27306910).', '', '0', NULL),","The BRCA1 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793). Additionally, the BRCA1 gene has preliminary evidence supporting a correlation with autosomal recessive Fanconi anemia (MedGen UID: 1632414).  HBOC due to a clinically significant change in the BRCA1 gene is characterized by an increased risk of breast cancer (in both females and males), ovarian cancer, prostate cancer, pancreatic cancer and possibly melanoma when compared to individuals in the general population. The lifetime risk of breast cancer for females with a positive BRCA1 variant is 53-78% (PMID: 32676552, 33471974) and the chance of developing breast cancer again in their other breast (contralateral breast cancer) within 10 years after the first diagnosis is estimated to be 20-42% (PMID: 26700119). The lifetime risk to develop ovarian or fallopian tube cancer is 44-65% (PMID: 32676552). Males with HBOC due to a change in the BRCA1 gene have a 1-2% lifetime risk of developing breast cancer (PMID: 18042939) and an increased risk of prostate cancer, although specific lifetime risks are not clear (PMID: 30900310). Both males and females with a positive BRCA1 variant have a 3-4% lifetime risk of pancreatic cancer (PMID: 29922827, 27306910)."
BRCA2,"The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793) and autosomal recessive Fanconi anemia, type D1 (FA-D1) (MedGen UID: 325420).","Females with a pathogenic BRCA2 variant have a 44-80% lifetime risk of breast cancer (PMID: 32676552, 33471974). The risk for contralateral breast cancer 10 years after primary diagnosis is 10-30% (PMID: 26700119). The lifetime risk for ovarian, fallopian tube or peritoneal cancer is 19-46% (PMID: 32676552). Males have a 7-8% risk of breast cancer (PMID: 18042939) and a 22-32% risk of prostate cancer (PMID: 30900310). Both males and females have an increased risk of pancreatic cancer (4-9% lifetime risk) (PMID: 29922827, 27306910) and melanoma (lifetime risks are not established) (PMID: 10433620).","Biallelic pathogenic variants in BRCA2 are associated with a particularly severe form of Fanconi anemia (PMID: 16825431) characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). Risks of leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516), with up to a 97% risk of malignancy by 5 years of age (PMID: 16825431).",YES,,,"('BRCA2', 'The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793) and autosomal recessive Fanconi anemia, type D1 (FA-D1) (MedGen UID: 325420).', 'Females with a pathogenic BRCA2 variant have a 44-80% lifetime risk of breast cancer (PMID: 32676552, 33471974). The risk for contralateral breast cancer 10 years after primary diagnosis is 10-30% (PMID: 26700119). The lifetime risk for ovarian, fallopian tube or peritoneal cancer is 19-46% (PMID: 32676552). Males have a 7-8% risk of breast cancer (PMID: 18042939) and a 22-32% risk of prostate cancer (PMID: 30900310). Both males and females have an increased risk of pancreatic cancer (4-9% lifetime risk) (PMID: 29922827, 27306910) and melanoma (lifetime risks are not established) (PMID: 10433620).', 'Biallelic pathogenic variants in BRCA2 are associated with a particularly severe form of Fanconi anemia (PMID: 16825431) characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). Risks of leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516), with up to a 97% risk of malignancy by 5 years of age (PMID: 16825431).', '1', NULL),","The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793) and autosomal recessive Fanconi anemia, type D1 (FA-D1) (MedGen UID: 325420).  Females with a pathogenic BRCA2 variant have a 44-80% lifetime risk of breast cancer (PMID: 32676552, 33471974). The risk for contralateral breast cancer 10 years after primary diagnosis is 10-30% (PMID: 26700119). The lifetime risk for ovarian, fallopian tube or peritoneal cancer is 19-46% (PMID: 32676552). Males have a 7-8% risk of breast cancer (PMID: 18042939) and a 22-32% risk of prostate cancer (PMID: 30900310). Both males and females have an increased risk of pancreatic cancer (4-9% lifetime risk) (PMID: 29922827, 27306910) and melanoma (lifetime risks are not established) (PMID: 10433620).  Biallelic pathogenic variants in BRCA2 are associated with a particularly severe form of Fanconi anemia (PMID: 16825431) characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). Risks of leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516), with up to a 97% risk of malignancy by 5 years of age (PMID: 16825431)."
BRIP1,"The BRIP1 gene is associated with autosomal dominant predisposition to ovarian cancer (PMID: 30733081) and autosomal recessive Fanconi anemia (MedGen UID: 323015). There is also evidence suggesting BRIP1 is associated with autosomal dominant predisposition to breast and prostate cancer (PMID: 17033622, 28418444, 30733081, 32708810, 32853339). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","Females with a pathogenic BRIP1 variant have approximately a 6-13% risk of ovarian cancer (PMID: 26315354, 27296296, 32359370).","Autosomal recessive Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risk of leukemia and early onset solid tumors is significantly elevated (PMID: 20507306, 12393424, 12393516).",YES,,,"('BRIP1', 'The BRIP1 gene is associated with autosomal dominant predisposition to ovarian cancer (PMID: 30733081) and autosomal recessive Fanconi anemia (MedGen UID: 323015). There is also evidence suggesting BRIP1 is associated with autosomal dominant predisposition to breast and prostate cancer (PMID: 17033622, 28418444, 30733081, 32708810, 32853339). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                        ', 'Females with a pathogenic BRIP1 variant have approximately a 6-13% risk of ovarian cancer (PMID: 26315354, 27296296, 32359370). ', 'Autosomal recessive Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risk of leukemia and early onset solid tumors is significantly elevated (PMID: 20507306, 12393424, 12393516).', '1', NULL),","The BRIP1 gene is associated with autosomal dominant predisposition to ovarian cancer (PMID: 30733081) and autosomal recessive Fanconi anemia (MedGen UID: 323015). There is also evidence suggesting BRIP1 is associated with autosomal dominant predisposition to breast and prostate cancer (PMID: 17033622, 28418444, 30733081, 32708810, 32853339). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                          Females with a pathogenic BRIP1 variant have approximately a 6-13% risk of ovarian cancer (PMID: 26315354, 27296296, 32359370).   Autosomal recessive Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risk of leukemia and early onset solid tumors is significantly elevated (PMID: 20507306, 12393424, 12393516)."
CASR,"The CASR gene is associated with a spectrum of disorders including autosomal dominant familial hypocalciuric hypercalcemia (FHH) (MedGen UID: 369200), autosomal dominant hypocalcemia (ADH) (MedGen UID: 87438), ADH with Bartter syndrome (MedGen UID: 811594), autosomal recessive neonatal severe hyperparathyroidism (NSHPT) (MedGen UID: 331326), and possibly familial isolated hyperparathyroidism (FIHP) (PMID: 14985373, 21521328). There is also evidence suggesting CASR is associated with autosomal dominant idiopathic generalized epilepsy (PMID: 18756473) and chronic pancreatitis (PMID: 14641934, 16497624). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","CASR-related conditions include multiple disorders resulting in abnormal calcium levels. Pathogenic loss-of-function (LOF) variants cause FHH, characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130). NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).

Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).",,NO,,,"('CASR', 'The CASR gene is associated with a spectrum of disorders including autosomal dominant familial hypocalciuric hypercalcemia (FHH) (MedGen UID: 369200), autosomal dominant hypocalcemia (ADH) (MedGen UID: 87438), ADH with Bartter syndrome (MedGen UID: 811594), autosomal recessive neonatal severe hyperparathyroidism (NSHPT) (MedGen UID: 331326), and possibly familial isolated hyperparathyroidism (FIHP) (PMID: 14985373, 21521328). There is also evidence suggesting CASR is associated with autosomal dominant idiopathic generalized epilepsy (PMID: 18756473) and chronic pancreatitis (PMID: 14641934, 16497624). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'CASR-related conditions include multiple disorders resulting in abnormal calcium levels. Pathogenic loss-of-function (LOF) variants cause FHH, characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130). NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).

Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).', '', '1', NULL),","The CASR gene is associated with a spectrum of disorders including autosomal dominant familial hypocalciuric hypercalcemia (FHH) (MedGen UID: 369200), autosomal dominant hypocalcemia (ADH) (MedGen UID: 87438), ADH with Bartter syndrome (MedGen UID: 811594), autosomal recessive neonatal severe hyperparathyroidism (NSHPT) (MedGen UID: 331326), and possibly familial isolated hyperparathyroidism (FIHP) (PMID: 14985373, 21521328). There is also evidence suggesting CASR is associated with autosomal dominant idiopathic generalized epilepsy (PMID: 18756473) and chronic pancreatitis (PMID: 14641934, 16497624). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  CASR-related conditions include multiple disorders resulting in abnormal calcium levels. Pathogenic loss-of-function (LOF) variants cause FHH, characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130). NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).

Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130)."
CDC73,"The CDC73 gene is associated with autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor.",,NO,,,"('CDC73', 'The CDC73 gene is associated with autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor.', '', '0', NULL),","The CDC73 gene is associated with autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor."
CDH1,"The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).","The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974).",,YES,,,"('CDH1', 'The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).', 'The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974).', '', '0', NULL),","The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).  The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974)."
CDK4,The CDK4 gene is associated with autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).,"CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks.",,NO,,,"('CDK4', 'The CDK4 gene is associated with autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).', 'CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks.', '', '1', NULL),","The CDK4 gene is associated with autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).  CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks."
CDKN1B,The CDKN1B gene is associated with autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).,"MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918).",,NO,,,"('CDKN1B', 'The CDKN1B gene is associated with autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).', 'MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918).', '', '0', NULL),","The CDKN1B gene is associated with autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).  MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918)."
CDKN1C,"The CDKN1C gene is associated with autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562) and IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).","BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276).",,NO,,,"('CDKN1C', 'The CDKN1C gene is associated with autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562) and IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).', 'BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276).', '', '0', NULL),","The CDKN1C gene is associated with autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562) and IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).  BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276)."
CDKN2A/p14,"The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.","The variant identified in this individual impacts the p14ARF protein, which is associated with melanoma-NST syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and neural system tumors including astrocytoma and nerve sheath tumors (PMID: 9622062, 11136714, 17047042). Variants that only affect the p14ARF transcript are not known to be associated with pancreatic cancer. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants are currently unknown.",,NO,,,"('CDKN2A/p14', 'The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.', 'The variant identified in this individual impacts the p14ARF protein, which is associated with melanoma-NST syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and neural system tumors including astrocytoma and nerve sheath tumors (PMID: 9622062, 11136714, 17047042). Variants that only affect the p14ARF transcript are not known to be associated with pancreatic cancer. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants are currently unknown.', '', '0', NULL),","The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.  The variant identified in this individual impacts the p14ARF protein, which is associated with melanoma-NST syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and neural system tumors including astrocytoma and nerve sheath tumors (PMID: 9622062, 11136714, 17047042). Variants that only affect the p14ARF transcript are not known to be associated with pancreatic cancer. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants are currently unknown."
CDKN2A/p16,"The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.","The variant identified in this individual impacts the p16INK4a protein, which is associated with melanoma-pancreatic cancer syndrome, also known as familial atypical multiple mole melanoma (FAMMM) syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and pancreatic cancer. The lifetime risk of melanoma is 28-67%; the risk of pancreatic cancer is approximately 17% (PMID: 12072543, 16234564, 10956390, 24935963) although one study has suggested the risk may be up to 58% (PMID: 21150883). Variants affecting only the p16INK4a transcript are not known to be associated with neural system tumors. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants is currently unknown.",,NO,Hide All due to content alignment needs,,"('CDKN2A/p16', 'The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.', 'The variant identified in this individual impacts the p16INK4a protein, which is associated with melanoma-pancreatic cancer syndrome, also known as familial atypical multiple mole melanoma (FAMMM) syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and pancreatic cancer. The lifetime risk of melanoma is 28-67%; the risk of pancreatic cancer is approximately 17% (PMID: 12072543, 16234564, 10956390, 24935963) although one study has suggested the risk may be up to 58% (PMID: 21150883). Variants affecting only the p16INK4a transcript are not known to be associated with neural system tumors. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants is currently unknown. ', '', '0', ''),","The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.  The variant identified in this individual impacts the p16INK4a protein, which is associated with melanoma-pancreatic cancer syndrome, also known as familial atypical multiple mole melanoma (FAMMM) syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and pancreatic cancer. The lifetime risk of melanoma is 28-67%; the risk of pancreatic cancer is approximately 17% (PMID: 12072543, 16234564, 10956390, 24935963) although one study has suggested the risk may be up to 58% (PMID: 21150883). Variants affecting only the p16INK4a transcript are not known to be associated with neural system tumors. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants is currently unknown."
CEBPA,The CEBPA gene is associated with autosomal dominant predisposition to familial acute myeloid leukemia (AML) (MedGen UID: 9730).,"Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409).",,NO,,,"('CEBPA', 'The CEBPA gene is associated with autosomal dominant predisposition to familial acute myeloid leukemia (AML) (MedGen UID: 9730).', 'Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409).', '', '0', NULL),","The CEBPA gene is associated with autosomal dominant predisposition to familial acute myeloid leukemia (AML) (MedGen UID: 9730).  Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409)."
CFTR,"The CFTR gene is associated with autosomal recessive cystic fibrosis (CF) (MedGen UID: 41393) and congenital bilateral absence of the vas deferens (CBAVD) (MedGen UID: 98021). Additionally, CFTR is associated with an increased risk for chronic pancreatitis (PMID: 17003641, 11729110).","Cystic fibrosis (CF) is usually a childhood onset disease characterized by the buildup of mucus that can damage the digestive and respiratory systems. Milder forms of CFTR-related disorders include congenital absence of the vas deferens (CAVD) (MedGen UID: 430259) associated with infertility, respiratory manifestations, and hereditary pancreatitis (MedGen UID: 116056). Pathogenic variants in CFTR may confer an approximately 4-10 fold increased risk for chronic pancreatitis in heterozygous carriers (PMID: 20977904, 21520337, 11729110), although the absolute risk of pancreatitis remains low (less than 1 in 100; PMID: 31882447). Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The combination of variants identified in an affected individual impacts the observed clinical features and severity of the disorders (PMID: 20301428, 24624459).",,NO,,,"('CFTR', 'The CFTR gene is associated with autosomal recessive cystic fibrosis (CF) (MedGen UID: 41393) and congenital bilateral absence of the vas deferens (CBAVD) (MedGen UID: 98021). Additionally, CFTR is associated with an increased risk for chronic pancreatitis (PMID: 17003641, 11729110). ', 'Cystic fibrosis (CF) is usually a childhood onset disease characterized by the buildup of mucus that can damage the digestive and respiratory systems. Milder forms of CFTR-related disorders include congenital absence of the vas deferens (CAVD) (MedGen UID: 430259) associated with infertility, respiratory manifestations, and hereditary pancreatitis (MedGen UID: 116056). Pathogenic variants in CFTR may confer an approximately 4-10 fold increased risk for chronic pancreatitis in heterozygous carriers (PMID: 20977904, 21520337, 11729110), although the absolute risk of pancreatitis remains low (less than 1 in 100; PMID: 31882447). Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The combination of variants identified in an affected individual impacts the observed clinical features and severity of the disorders (PMID: 20301428, 24624459).', '', '0', NULL),","The CFTR gene is associated with autosomal recessive cystic fibrosis (CF) (MedGen UID: 41393) and congenital bilateral absence of the vas deferens (CBAVD) (MedGen UID: 98021). Additionally, CFTR is associated with an increased risk for chronic pancreatitis (PMID: 17003641, 11729110).   Cystic fibrosis (CF) is usually a childhood onset disease characterized by the buildup of mucus that can damage the digestive and respiratory systems. Milder forms of CFTR-related disorders include congenital absence of the vas deferens (CAVD) (MedGen UID: 430259) associated with infertility, respiratory manifestations, and hereditary pancreatitis (MedGen UID: 116056). Pathogenic variants in CFTR may confer an approximately 4-10 fold increased risk for chronic pancreatitis in heterozygous carriers (PMID: 20977904, 21520337, 11729110), although the absolute risk of pancreatitis remains low (less than 1 in 100; PMID: 31882447). Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The combination of variants identified in an affected individual impacts the observed clinical features and severity of the disorders (PMID: 20301428, 24624459)."
CHEK2,"The CHEK2 gene is associated with autosomal dominant predisposition to breast, colon, thyroid and prostate cancer (PMID: 15492928, 18759107, 21807500, 21876083, 25431674). Additionally, there is evidence supporting a correlation with CHEK2 and autosomal dominant predisposition to ovarian, renal and urinary tract cancer (PMID: 26681312, 27632928, 26424751, 11719428, 15492928, 29978187); however, the available evidence is insufficient to make a determination regarding these relationships.","The lifetime risk of breast cancer in females with a pathogenic CHEK2 variant is 20-44% (PMID: 18172190, 21876083, 33471974). There is also an increased risk for male breast, colorectal, prostate and thyroid cancers; however, lifetime risks are not established (PMID: 18759107, 21807500, 23713947, 15492928, 25431674). While there is evidence to suggest an increased risk for various primary cancers among homozygotes and compound heterozygotes for most pathogenic CHEK2 variants, these risks are not established (PMID: 30858171, 27900359). For the well-studied c.1100del variant, homozygotes have approximately a 4-6 fold increased risk of breast cancer (PMID: 22058428, 23652375).",,YES,Hide Prostate,"[""Prostate""]","('CHEK2', 'The CHEK2 gene is associated with autosomal dominant predisposition to breast, colon, thyroid and prostate cancer (PMID: 15492928, 18759107, 21807500, 21876083, 25431674). Additionally, there is evidence supporting a correlation with CHEK2 and autosomal dominant predisposition to ovarian, renal and urinary tract cancer (PMID: 26681312, 27632928, 26424751, 11719428, 15492928, 29978187); however, the available evidence is insufficient to make a determination regarding these relationships.', 'The lifetime risk of breast cancer in females with a pathogenic CHEK2 variant is 20-44% (PMID: 18172190, 21876083, 33471974). There is also an increased risk for male breast, colorectal, prostate and thyroid cancers; however, lifetime risks are not established (PMID: 18759107, 21807500, 23713947, 15492928, 25431674). While there is evidence to suggest an increased risk for various primary cancers among homozygotes and compound heterozygotes for most pathogenic CHEK2 variants, these risks are not established (PMID: 30858171, 27900359). For the well-studied c.1100del variant, homozygotes have approximately a 4-6 fold increased risk of breast cancer (PMID: 22058428, 23652375).', '', '0', '[""Prostate""]'),","The CHEK2 gene is associated with autosomal dominant predisposition to breast, colon, thyroid and prostate cancer (PMID: 15492928, 18759107, 21807500, 21876083, 25431674). Additionally, there is evidence supporting a correlation with CHEK2 and autosomal dominant predisposition to ovarian, renal and urinary tract cancer (PMID: 26681312, 27632928, 26424751, 11719428, 15492928, 29978187); however, the available evidence is insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic CHEK2 variant is 20-44% (PMID: 18172190, 21876083, 33471974). There is also an increased risk for male breast, colorectal, prostate and thyroid cancers; however, lifetime risks are not established (PMID: 18759107, 21807500, 23713947, 15492928, 25431674). While there is evidence to suggest an increased risk for various primary cancers among homozygotes and compound heterozygotes for most pathogenic CHEK2 variants, these risks are not established (PMID: 30858171, 27900359). For the well-studied c.1100del variant, homozygotes have approximately a 4-6 fold increased risk of breast cancer (PMID: 22058428, 23652375)."
CTNNA1,"The CTNNA1 gene is associated with autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). Additionally, CTNNA1 has preliminary evidence supporting a correlation with autosomal dominant hereditary diffuse gastric cancer; however, the available evidence is insufficient to make a determination regarding this relationship (PMID: 23208944, 26182300, 32051609). This result should be considered in the context of personal and family history of diffuse gastric cancer and may warrant additional surveillance (PMID: 32758476). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.","Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986).",,NO,,,"('CTNNA1', 'The CTNNA1 gene is associated with autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). Additionally, CTNNA1 has preliminary evidence supporting a correlation with autosomal dominant hereditary diffuse gastric cancer; however, the available evidence is insufficient to make a determination regarding this relationship (PMID: 23208944, 26182300, 32051609). This result should be considered in the context of personal and family history of diffuse gastric cancer and may warrant additional surveillance (PMID: 32758476). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.', 'Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986).', '', '1', NULL),","The CTNNA1 gene is associated with autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). Additionally, CTNNA1 has preliminary evidence supporting a correlation with autosomal dominant hereditary diffuse gastric cancer; however, the available evidence is insufficient to make a determination regarding this relationship (PMID: 23208944, 26182300, 32051609). This result should be considered in the context of personal and family history of diffuse gastric cancer and may warrant additional surveillance (PMID: 32758476). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.  Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986)."
CTRC,The CTRC gene is associated with an increased risk for chronic pancreatitis (MedGen UID: 116056).,"Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Penetrance and inheritance patterns of this gene are not well established, but individuals with a pathogenic loss-of-function CTRC variant may have an increased risk for chronic pancreatitis, particularly in the presence of other genetic and environmental risk factors (PMID: 18059268, 18172691, 22942235). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203).",,NO,,,"('CTRC', 'The CTRC gene is associated with an increased risk for chronic pancreatitis (MedGen UID: 116056).', 'Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Penetrance and inheritance patterns of this gene are not well established, but individuals with a pathogenic loss-of-function CTRC variant may have an increased risk for chronic pancreatitis, particularly in the presence of other genetic and environmental risk factors (PMID: 18059268, 18172691, 22942235). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203).', '', '0', NULL),","The CTRC gene is associated with an increased risk for chronic pancreatitis (MedGen UID: 116056).  Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Penetrance and inheritance patterns of this gene are not well established, but individuals with a pathogenic loss-of-function CTRC variant may have an increased risk for chronic pancreatitis, particularly in the presence of other genetic and environmental risk factors (PMID: 18059268, 18172691, 22942235). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203)."
DDX41,The DDX41 gene is associated with autosomal dominant familial myeloproliferative/lymphoproliferative neoplasms (MPLPF) (MedGen UID: 895780).,"MPLPF is characterized by hereditary predisposition to adult-onset myeloid malignancies, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and in rare cases, lymphoma (PMID: 26712909). The disorder shows incomplete penetrance and the lifetime cancer risk is not known (PMID: 27133828). For information regarding management and surveillance suggestions for individuals with pathogenic variants in DDX41, please refer to PMID: 28600339.",,NO,,,"('DDX41', 'The DDX41 gene is associated with autosomal dominant familial myeloproliferative/lymphoproliferative neoplasms (MPLPF) (MedGen UID: 895780).', 'MPLPF is characterized by hereditary predisposition to adult-onset myeloid malignancies, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and in rare cases, lymphoma (PMID: 26712909). The disorder shows incomplete penetrance and the lifetime cancer risk is not known (PMID: 27133828). For information regarding management and surveillance suggestions for individuals with pathogenic variants in DDX41, please refer to PMID: 28600339.', '', '0', NULL),","The DDX41 gene is associated with autosomal dominant familial myeloproliferative/lymphoproliferative neoplasms (MPLPF) (MedGen UID: 895780).  MPLPF is characterized by hereditary predisposition to adult-onset myeloid malignancies, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and in rare cases, lymphoma (PMID: 26712909). The disorder shows incomplete penetrance and the lifetime cancer risk is not known (PMID: 27133828). For information regarding management and surveillance suggestions for individuals with pathogenic variants in DDX41, please refer to PMID: 28600339."
DICER1,The DICER1 gene is associated with autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).,"DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma.",,NO,,,"('DICER1', 'The DICER1 gene is associated with autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).', 'DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma.', '', '0', NULL),","The DICER1 gene is associated with autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).  DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma."
DIS3L2,The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).,"Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370).",,NO,,,"('DIS3L2', 'The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).', 'Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370).', '', '0', NULL),","The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).  Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370)."
EGFR,The EGFR gene is associated with autosomal dominant predisposition to lung cancer (MedGen UID: 472093) and autosomal recessive neonatal inflammatory skin and bowel disease (MedGen UID: 863567).,"Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited. GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease.",,NO,,,"('EGFR', 'The EGFR gene is associated with autosomal dominant predisposition to lung cancer (MedGen UID: 472093) and autosomal recessive neonatal inflammatory skin and bowel disease (MedGen UID: 863567).', 'Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited. GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease.', '', '0', NULL),","The EGFR gene is associated with autosomal dominant predisposition to lung cancer (MedGen UID: 472093) and autosomal recessive neonatal inflammatory skin and bowel disease (MedGen UID: 863567).  Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited. GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease."
EPCAM,"Deletions that include exon 9 of the EPCAM gene are known to cause autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer, or HNPCC) (MedGen UID: 412966) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553). EPCAM is also associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031). The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).","Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).","CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897). Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020).",NO,,,"('EPCAM', 'Deletions that include exon 9 of the EPCAM gene are known to cause autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer, or HNPCC) (MedGen UID: 412966) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553). EPCAM is also associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031). The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).', 'Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).', 'CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897). Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020).', '0', NULL),","Deletions that include exon 9 of the EPCAM gene are known to cause autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer, or HNPCC) (MedGen UID: 412966) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553). EPCAM is also associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031). The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).  Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897). Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020)."
FANCA,The FANCA gene is associated with autosomal recessive Fanconi anemia type A (FA-A) (MedGen UID: 483333).,"Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).",,NO,,,"('FANCA', 'The FANCA gene is associated with autosomal recessive Fanconi anemia type A (FA-A) (MedGen UID: 483333).', 'Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).									', '', '0', NULL),","The FANCA gene is associated with autosomal recessive Fanconi anemia type A (FA-A) (MedGen UID: 483333).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516)."
FANCC,"The FANCC gene is associated with autosomal recessive Fanconi anemia (MedGen UID: 483324). There is also evidence suggesting FANCC is associated with autosomal dominant predisposition to breast, ovarian and pancreatic cancer (PMID: 30733081, 15695377, 12750283). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).",,NO,,,"('FANCC', 'The FANCC gene is associated with autosomal recessive Fanconi anemia (MedGen UID: 483324). There is also evidence suggesting FANCC is associated with autosomal dominant predisposition to breast, ovarian and pancreatic cancer (PMID: 30733081, 15695377, 12750283). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).', '', '0', NULL),","The FANCC gene is associated with autosomal recessive Fanconi anemia (MedGen UID: 483324). There is also evidence suggesting FANCC is associated with autosomal dominant predisposition to breast, ovarian and pancreatic cancer (PMID: 30733081, 15695377, 12750283). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516)."
FANCM,"The FANCM gene is associated with an autosomal recessive condition characterized by an increased risk for malignancy and infertility (OMIM: 618086). Additionally, there is preliminary evidence that FANCM is associated with autosomal dominant predisposition to breast cancer (PMID: 23409019, 25288723) and autosomal recessive Fanconi anemia (PMID: 16116422, 19423727, 21681190). The data, however, are insufficient to make a determination regarding these relationships.","Biallelic variants in FANCM have been described in individuals with variable features including malignancy, infertility and chromosome fragility (PMID: 30075111, 29231814, 28837162, 29895858, 28837157). The most common associated malignancies include cancers of the head, neck and breast; however, other cancer types have been reported (PMID: 28837162, 28837157). Several affected individuals have demonstrated reduced fertility (PMID: 30075111, 29231814, 28837162, 29895858). Chromosomal breakage due to hypersensitivity to crosslink-inducing agents has been observed (PMID: 29231814, 29895858, 28837157). Data regarding lifetime risks and management of autosomal recessive FANCM-related conditions are not yet established.",,NO,,,"('FANCM', 'The FANCM gene is associated with an autosomal recessive condition characterized by an increased risk for malignancy and infertility (OMIM: 618086). Additionally, there is preliminary evidence that FANCM is associated with autosomal dominant predisposition to breast cancer (PMID: 23409019, 25288723) and autosomal recessive Fanconi anemia (PMID: 16116422, 19423727, 21681190). The data, however, are insufficient to make a determination regarding these relationships.', 'Biallelic variants in FANCM have been described in individuals with variable features including malignancy, infertility and chromosome fragility (PMID: 30075111, 29231814, 28837162, 29895858, 28837157). The most common associated malignancies include cancers of the head, neck and breast; however, other cancer types have been reported (PMID: 28837162, 28837157). Several affected individuals have demonstrated reduced fertility (PMID: 30075111, 29231814, 28837162, 29895858). Chromosomal breakage due to hypersensitivity to crosslink-inducing agents has been observed (PMID: 29231814, 29895858, 28837157). Data regarding lifetime risks and management of autosomal recessive FANCM-related conditions are not yet established.', '', '0', NULL),","The FANCM gene is associated with an autosomal recessive condition characterized by an increased risk for malignancy and infertility (OMIM: 618086). Additionally, there is preliminary evidence that FANCM is associated with autosomal dominant predisposition to breast cancer (PMID: 23409019, 25288723) and autosomal recessive Fanconi anemia (PMID: 16116422, 19423727, 21681190). The data, however, are insufficient to make a determination regarding these relationships.  Biallelic variants in FANCM have been described in individuals with variable features including malignancy, infertility and chromosome fragility (PMID: 30075111, 29231814, 28837162, 29895858, 28837157). The most common associated malignancies include cancers of the head, neck and breast; however, other cancer types have been reported (PMID: 28837162, 28837157). Several affected individuals have demonstrated reduced fertility (PMID: 30075111, 29231814, 28837162, 29895858). Chromosomal breakage due to hypersensitivity to crosslink-inducing agents has been observed (PMID: 29231814, 29895858, 28837157). Data regarding lifetime risks and management of autosomal recessive FANCM-related conditions are not yet established."
FH,The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).,"HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.","FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay.",NO,,,"('FH', 'The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).', 'HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.', 'FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay.', '0', NULL),","The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).  HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.  FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay."
FLCN,"The FLCN gene is associated with autosomal dominant Birt-Hogg-Dubé (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.","BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728).",,NO,,,"('FLCN', 'The FLCN gene is associated with autosomal dominant Birt-Hogg-Dubé (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.', 'BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728).', '', '0', NULL),","The FLCN gene is associated with autosomal dominant Birt-Hogg-Dubé (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.  BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728)."
GALNT12,"The GALNT12 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 19617566, 22461326, 29749045).",,,NO,,,"('GALNT12', 'The GALNT12 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 19617566, 22461326, 29749045).', '', '', '0', NULL),","The GALNT12 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 19617566, 22461326, 29749045)."
GATA2,The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).,"GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML). Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646).",,NO,,,"('GATA2', 'The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).', 'GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML). Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646).', '', '0', NULL),","The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).  GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML). Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646)."
GEN1,"The GEN1 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to prostate cancer (PMID: 27433846).",,,NO,,,"('GEN1', 'The GEN1 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to prostate cancer (PMID: 27433846).', '', '', '0', NULL),","The GEN1 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to prostate cancer (PMID: 27433846)."
GPC3,The GPC3 gene is associated with X-linked recessive Simpson-Golabi-Behmel syndrome (MedGen UID: 162917).,"Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).

Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).",,NO,,,"('GPC3', 'The GPC3 gene is associated with X-linked recessive Simpson-Golabi-Behmel syndrome (MedGen UID: 162917).', 'Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).

Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).', '', '0', NULL),","The GPC3 gene is associated with X-linked recessive Simpson-Golabi-Behmel syndrome (MedGen UID: 162917).  Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).

Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977)."
GREM1,"The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).",Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established.,,NO,,,"('GREM1', 'The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3'' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).', 'Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established.', '', '0', NULL),","The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).  Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established."
HOXB13,The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).,,,NO,,,"('HOXB13', 'The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).', '', '', '0', NULL),",The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).
HRAS,The HRAS gene is associated with autosomal dominant Costello syndrome (MedGen UID: 108454).,"Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge.",,NO,,,"('HRAS', 'The HRAS gene is associated with autosomal dominant Costello syndrome (MedGen UID: 108454).', 'Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge.', '', '0', NULL),","The HRAS gene is associated with autosomal dominant Costello syndrome (MedGen UID: 108454).  Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge."
KIF1B,"The KIF1B gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (PMID: 24694336), neuroblastoma (PMID: 18614535, 18334619, 24469107), and Charcot-Marie-Tooth disease (CMT) (PMID: 30373780).",,,NO,,,"('KIF1B', 'The KIF1B gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (PMID: 24694336), neuroblastoma (PMID: 18614535, 18334619, 24469107), and Charcot-Marie-Tooth disease (CMT) (PMID: 30373780).', '', '', '0', NULL),","The KIF1B gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (PMID: 24694336), neuroblastoma (PMID: 18614535, 18334619, 24469107), and Charcot-Marie-Tooth disease (CMT) (PMID: 30373780)."
KIT,"The KIT gene is associated with autosomal dominant piebaldism (MedGen UID: 36361), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and familial mastocytosis (MedGen UID: 9902).","Pathogenic loss-of-function (LOF) variants in KIT are associated with piebaldism, a rare condition characterized by patchy absence of melanocytes in the skin and hair. These unpigmented areas are typically present at birth and do not increase in size or number (PMID: 19555431, 7529964, 7525736). LOF pathogenic KIT variants are generally not associated with familial GIST or mastocytosis (PMID: 15241338). 

Pathogenic gain-of-function (GOF) KIT variants are associated with familial GIST and familial mastocytosis. Familial GIST is a primarily adult-onset condition characterized by sarcomas of the stomach and small bowel that may be benign or malignant (PMID: 23648119, 26833487, 9438854). Familial mastocytosis causes abnormal accumulation of mast cells in the skin and bone marrow (PMID: 27777718, 28031180). In childhood, this condition is known as cutaneous mastocytosis because it manifests in the skin, often resolving by puberty. Adult-onset cases are known as systemic mastocytosis due to involvement of the bone marrow and skin, with potential risks for hematologic malignancy (PMID: 27777718, 28031180). Some individuals with pathogenic GOF KIT variants may present with features of both GIST and mastocytosis (PMID: 27777718). Pathogenic GOF variants in KIT are generally not associated with piebaldism (PMID: 15241338).",,NO,,,"('KIT', 'The KIT gene is associated with autosomal dominant piebaldism (MedGen UID: 36361), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and familial mastocytosis (MedGen UID: 9902).', 'Pathogenic loss-of-function (LOF) variants in KIT are associated with piebaldism, a rare condition characterized by patchy absence of melanocytes in the skin and hair. These unpigmented areas are typically present at birth and do not increase in size or number (PMID: 19555431, 7529964, 7525736). LOF pathogenic KIT variants are generally not associated with familial GIST or mastocytosis (PMID: 15241338). 

Pathogenic gain-of-function (GOF) KIT variants are associated with familial GIST and familial mastocytosis. Familial GIST is a primarily adult-onset condition characterized by sarcomas of the stomach and small bowel that may be benign or malignant (PMID: 23648119, 26833487, 9438854). Familial mastocytosis causes abnormal accumulation of mast cells in the skin and bone marrow (PMID: 27777718, 28031180). In childhood, this condition is known as cutaneous mastocytosis because it manifests in the skin, often resolving by puberty. Adult-onset cases are known as systemic mastocytosis due to involvement of the bone marrow and skin, with potential risks for hematologic malignancy (PMID: 27777718, 28031180). Some individuals with pathogenic GOF KIT variants may present with features of both GIST and mastocytosis (PMID: 27777718). Pathogenic GOF variants in KIT are generally not associated with piebaldism (PMID: 15241338).', '', '0', NULL),","The KIT gene is associated with autosomal dominant piebaldism (MedGen UID: 36361), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and familial mastocytosis (MedGen UID: 9902).  Pathogenic loss-of-function (LOF) variants in KIT are associated with piebaldism, a rare condition characterized by patchy absence of melanocytes in the skin and hair. These unpigmented areas are typically present at birth and do not increase in size or number (PMID: 19555431, 7529964, 7525736). LOF pathogenic KIT variants are generally not associated with familial GIST or mastocytosis (PMID: 15241338). 

Pathogenic gain-of-function (GOF) KIT variants are associated with familial GIST and familial mastocytosis. Familial GIST is a primarily adult-onset condition characterized by sarcomas of the stomach and small bowel that may be benign or malignant (PMID: 23648119, 26833487, 9438854). Familial mastocytosis causes abnormal accumulation of mast cells in the skin and bone marrow (PMID: 27777718, 28031180). In childhood, this condition is known as cutaneous mastocytosis because it manifests in the skin, often resolving by puberty. Adult-onset cases are known as systemic mastocytosis due to involvement of the bone marrow and skin, with potential risks for hematologic malignancy (PMID: 27777718, 28031180). Some individuals with pathogenic GOF KIT variants may present with features of both GIST and mastocytosis (PMID: 27777718). Pathogenic GOF variants in KIT are generally not associated with piebaldism (PMID: 15241338)."
LZTR1 - Gain of Function,"The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).","Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).",,NO,,,"('LZTR1 - Gain of Function', 'The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								', 'Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).', '', '0', NULL),","The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								  Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612)."
LZTR1 - Loss of Function,"The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).","Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).",,NO,,,"('LZTR1 - Loss of Function', 'The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								', 'Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).', '', '0', NULL),","The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								  Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612)."
MAX,"The MAX gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). There is also evidence suggesting MAX is associated with autosomal dominant predisposition to renal cancer (PMID: 28973655) and pituitary adenomas (PMID: 32201880). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","MAX-associated PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964). While both males and females can pass this variant on to their children, there is evidence suggesting the risks of developing MAX-associated tumors are greatest for those who inherit the variant from their father (PMID: 22452945, 33493868).",,NO,,,"('MAX', 'The MAX gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). There is also evidence suggesting MAX is associated with autosomal dominant predisposition to renal cancer (PMID: 28973655) and pituitary adenomas (PMID: 32201880). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'MAX-associated PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964). While both males and females can pass this variant on to their children, there is evidence suggesting the risks of developing MAX-associated tumors are greatest for those who inherit the variant from their father (PMID: 22452945, 33493868).', '', '0', NULL),","The MAX gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). There is also evidence suggesting MAX is associated with autosomal dominant predisposition to renal cancer (PMID: 28973655) and pituitary adenomas (PMID: 32201880). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MAX-associated PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964). While both males and females can pass this variant on to their children, there is evidence suggesting the risks of developing MAX-associated tumors are greatest for those who inherit the variant from their father (PMID: 22452945, 33493868)."
MEN1,"The MEN1 gene is associated with autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957) and familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Studies also suggest the MEN1 gene may be associated with autosomal dominant predisposition to thyroid cancer (PMID: 30608029) and paraganglioma-pheochromocytoma syndrome (PGL-PCC) (PMID: 22723327, 27572829, 32130200). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).","MEN1 is also associated with autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448).",NO,,,"('MEN1', 'The MEN1 gene is associated with autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957) and familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Studies also suggest the MEN1 gene may be associated with autosomal dominant predisposition to thyroid cancer (PMID: 30608029) and paraganglioma-pheochromocytoma syndrome (PGL-PCC) (PMID: 22723327, 27572829, 32130200). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).', 'MEN1 is also associated with autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448).', '0', NULL),","The MEN1 gene is associated with autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957) and familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Studies also suggest the MEN1 gene may be associated with autosomal dominant predisposition to thyroid cancer (PMID: 30608029) and paraganglioma-pheochromocytoma syndrome (PGL-PCC) (PMID: 22723327, 27572829, 32130200). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).  MEN1 is also associated with autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448)."
MET,"The MET gene is associated with autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766) and autosomal recessive deafness (MedGen UID: 899875). Additionally, the MET gene has preliminary evidence supporting a correlation with arthrogryposis involving the upper limbs (PMID: 30777867). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).","Nonsyndromic deafness does not affect any other part of the body. Affected individuals are born with mild to profound hearing loss that typically does not worsen over time. Severity of deafness may vary, even among members of the same family. Intellect and life span are not impacted.",NO,,,"('MET', 'The MET gene is associated with autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766) and autosomal recessive deafness (MedGen UID: 899875). Additionally, the MET gene has preliminary evidence supporting a correlation with arthrogryposis involving the upper limbs (PMID: 30777867). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).                         ', 'Nonsyndromic deafness does not affect any other part of the body. Affected individuals are born with mild to profound hearing loss that typically does not worsen over time. Severity of deafness may vary, even among members of the same family. Intellect and life span are not impacted.', '0', NULL),","The MET gene is associated with autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766) and autosomal recessive deafness (MedGen UID: 899875). Additionally, the MET gene has preliminary evidence supporting a correlation with arthrogryposis involving the upper limbs (PMID: 30777867). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).                           Nonsyndromic deafness does not affect any other part of the body. Affected individuals are born with mild to profound hearing loss that typically does not worsen over time. Severity of deafness may vary, even among members of the same family. Intellect and life span are not impacted."
MITF,"The MITF gene is associated with autosomal dominant Waardenburg syndrome, type 2a (MedGen UID: 349786) and autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592). The c.952G>A (p.Glu318Lys) variant in MITF is associated with autosomal dominant predisposition to cutaneous malignant melanoma (MedGen UID: 463554).","Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).

COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised.",,NO,,,"('MITF', 'The MITF gene is associated with autosomal dominant Waardenburg syndrome, type 2a (MedGen UID: 349786) and autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592). The c.952G>A (p.Glu318Lys) variant in MITF is associated with autosomal dominant predisposition to cutaneous malignant melanoma (MedGen UID: 463554).', 'Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).

COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised.', '', '0', NULL),","The MITF gene is associated with autosomal dominant Waardenburg syndrome, type 2a (MedGen UID: 349786) and autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592). The c.952G>A (p.Glu318Lys) variant in MITF is associated with autosomal dominant predisposition to cutaneous malignant melanoma (MedGen UID: 463554).  Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).

COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised."
MLH1,"The MLH1 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).","MLH1-related Lynch syndrome is characterized by increased risk of various cancers including colorectal, endometrial, ovarian, urinary tract, gastrointestinal, brain and possibly prostate. Lifetime cancer risks include a 46–61% risk for colorectal cancer, a 5–7% risk for gastric cancer, a 6% risk for pancreatic cancer, up to an 11% risk for cancer of the small intestines, up to a 5% risk for urinary tract cancer, a 2–7% risk for bladder cancer, a 2–4% risk for cancer of the biliary tract and up to a 1.7% risk for brain/nervous system cancer. Affected females also have an increased risk of uterine/endometrial cancer (34-54%) and ovarian cancer (4–20%) (PMID: 21642682, 28754778, 28772289, 19900449, 26385421, 27013479, 18398828, 26657901,19900449, 31337882).","CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).",YES,"Hide Endometrial
Hide gastric for males only","[""Endometrial"", ""Gastric:Male""]","('MLH1', 'The MLH1 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).', 'MLH1-related Lynch syndrome is characterized by increased risk of various cancers including colorectal, endometrial, ovarian, urinary tract, gastrointestinal, brain and possibly prostate. Lifetime cancer risks include a 46–61% risk for colorectal cancer, a 5–7% risk for gastric cancer, a 6% risk for pancreatic cancer, up to an 11% risk for cancer of the small intestines, up to a 5% risk for urinary tract cancer, a 2–7% risk for bladder cancer, a 2–4% risk for cancer of the biliary tract and up to a 1.7% risk for brain/nervous system cancer. Affected females also have an increased risk of uterine/endometrial cancer (34-54%) and ovarian cancer (4–20%) (PMID: 21642682, 28754778, 28772289, 19900449, 26385421, 27013479, 18398828, 26657901,19900449, 31337882).', 'CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).', '0', '[""Endometrial"", ""Gastric:Male""]'),","The MLH1 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MLH1-related Lynch syndrome is characterized by increased risk of various cancers including colorectal, endometrial, ovarian, urinary tract, gastrointestinal, brain and possibly prostate. Lifetime cancer risks include a 46–61% risk for colorectal cancer, a 5–7% risk for gastric cancer, a 6% risk for pancreatic cancer, up to an 11% risk for cancer of the small intestines, up to a 5% risk for urinary tract cancer, a 2–7% risk for bladder cancer, a 2–4% risk for cancer of the biliary tract and up to a 1.7% risk for brain/nervous system cancer. Affected females also have an increased risk of uterine/endometrial cancer (34-54%) and ovarian cancer (4–20%) (PMID: 21642682, 28754778, 28772289, 19900449, 26385421, 27013479, 18398828, 26657901,19900449, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897)."
MRE11,"The MRE11 gene, formerly known as MRE11A, is associated with autosomal recessive ataxia-telangiectasia-like disorder (ATLD) (MedGen UID: 861227). There appears to be phenotypic overlap between ATLD and autosomal recessive Joubert syndrome (PMID: 22863007). Additionally, there are data supporting an association between MRE11 and autosomal dominant predisposition to breast and gynecologic cancer (PMID: 14684699, 24894818, 24549055, 25452441). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.","ATLD is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia (PMID: 15279810). Studies have demonstrated an increased susceptibility to radiation, consistent with a defect in the DNA repair pathway. While this disorder shares some phenotypic features with ataxia-telangiectasia, telangiectasias and immunodeficiency are not present in ATLD (PMID: 15279810, 10612394, 18652530).",,NO,,,"('MRE11', 'The MRE11 gene, formerly known as MRE11A, is associated with autosomal recessive ataxia-telangiectasia-like disorder (ATLD) (MedGen UID: 861227). There appears to be phenotypic overlap between ATLD and autosomal recessive Joubert syndrome (PMID: 22863007). Additionally, there are data supporting an association between MRE11 and autosomal dominant predisposition to breast and gynecologic cancer (PMID: 14684699, 24894818, 24549055, 25452441). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.                                                ', 'ATLD is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia (PMID: 15279810). Studies have demonstrated an increased susceptibility to radiation, consistent with a defect in the DNA repair pathway. While this disorder shares some phenotypic features with ataxia-telangiectasia, telangiectasias and immunodeficiency are not present in ATLD (PMID: 15279810, 10612394, 18652530).', '', '1', NULL),","The MRE11 gene, formerly known as MRE11A, is associated with autosomal recessive ataxia-telangiectasia-like disorder (ATLD) (MedGen UID: 861227). There appears to be phenotypic overlap between ATLD and autosomal recessive Joubert syndrome (PMID: 22863007). Additionally, there are data supporting an association between MRE11 and autosomal dominant predisposition to breast and gynecologic cancer (PMID: 14684699, 24894818, 24549055, 25452441). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.                                                  ATLD is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia (PMID: 15279810). Studies have demonstrated an increased susceptibility to radiation, consistent with a defect in the DNA repair pathway. While this disorder shares some phenotypic features with ataxia-telangiectasia, telangiectasias and immunodeficiency are not present in ATLD (PMID: 15279810, 10612394, 18652530)."
MSH2,"The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).","MSH2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovary, stomach, biliary tract, bladder, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks include a 33–52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).","CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).",YES,,,"('MSH2', 'The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).', 'MSH2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovary, stomach, biliary tract, bladder, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks include a 33–52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).', 'CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).', '0', NULL),","The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovary, stomach, biliary tract, bladder, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks include a 33–52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897)."
MSH3 - Monoallelic,"The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).",,NO,,,"('MSH3 - Monoallelic', 'The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).', '', '1', NULL),","The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653)."
MSH3 - Biallelic,"The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).",,NO,,,"('MSH3 - Biallelic', 'The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).', '', '1', NULL),","The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653)."
MSH6,"The MSH6 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 318886) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).","MSH6-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract, bladder, brain, and possibly prostate, stomach and small bowel. Estimated lifetime risks include a 10–44% risk of colorectal cancer, up to 5.5% risk of urinary tract cancer, up to an 8% risk of bladder cancer and up to a 2% risk of brain cancer. Affected females also have an increased risk of uterine/endometrial cancer (16-49%) and ovarian cancer (up to 13%) (PMID: 20028993, 21642682, 28754778, 20028993, 31204389, 31337882).","CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).",YES,,,"('MSH6', 'The MSH6 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 318886) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).', 'MSH6-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract, bladder, brain, and possibly prostate, stomach and small bowel. Estimated lifetime risks include a 10–44% risk of colorectal cancer, up to 5.5% risk of urinary tract cancer, up to an 8% risk of bladder cancer and up to a 2% risk of brain cancer. Affected females also have an increased risk of uterine/endometrial cancer (16-49%) and ovarian cancer (up to 13%) (PMID: 20028993, 21642682, 28754778, 20028993, 31204389, 31337882).', 'CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).', '0', NULL),","The MSH6 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 318886) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH6-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract, bladder, brain, and possibly prostate, stomach and small bowel. Estimated lifetime risks include a 10–44% risk of colorectal cancer, up to 5.5% risk of urinary tract cancer, up to an 8% risk of bladder cancer and up to a 2% risk of brain cancer. Affected females also have an increased risk of uterine/endometrial cancer (16-49%) and ovarian cancer (up to 13%) (PMID: 20028993, 21642682, 28754778, 20028993, 31204389, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897)."
MUTYH - Monoallelic,The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).,"MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).","Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.",NO,,,"('MUTYH - Monoallelic', 'The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).', 'MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).', 'Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.', '1', NULL),","The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).  MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).  Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks."
MUTYH - Biallelic,The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).,"MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).","Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.",NO,,,"('MUTYH - Biallelic', 'The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).', 'MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).', 'Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.', '0', NULL),","The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).  MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).  Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks."
NBN,"The NBN gene is associated with autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771). There is also evidence suggesting NBN may be associated with autosomal dominant predisposition to ovarian, endometrial and prostate cancer (PMID: 26720728, 29988077, 30733081, 31406321). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390).","Studies have previously suggested that females with a pathogenic variant in NBN may have autosomal dominant predisposition to breast cancer (PMID: 17957789, 21514219, 16770759, 23765759); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).",NO,,,"('NBN', 'The NBN gene is associated with autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771). There is also evidence suggesting NBN may be associated with autosomal dominant predisposition to ovarian, endometrial and prostate cancer (PMID: 26720728, 29988077, 30733081, 31406321). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390). ', 'Studies have previously suggested that females with a pathogenic variant in NBN may have autosomal dominant predisposition to breast cancer (PMID: 17957789, 21514219, 16770759, 23765759); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).', '0', NULL),","The NBN gene is associated with autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771). There is also evidence suggesting NBN may be associated with autosomal dominant predisposition to ovarian, endometrial and prostate cancer (PMID: 26720728, 29988077, 30733081, 31406321). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390).   Studies have previously suggested that females with a pathogenic variant in NBN may have autosomal dominant predisposition to breast cancer (PMID: 17957789, 21514219, 16770759, 23765759); however, more recent data have not supported this assertion (PMID: 33471974, 33471991)."
NF1,"The NF1 gene is associated with autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013), neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089) and Watson syndrome (MedGen UID: 107817).","NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).","Allelic NF1 disorders include Watson syndrome and NFNS. Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742). NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382). 

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results from blood or saliva specimens alone may not distinguish between germline and acquired variants in this gene and additional testing may be appropriate.",YES,,,"('NF1', 'The NF1 gene is associated with autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013), neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089) and Watson syndrome (MedGen UID: 107817). ', 'NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).           ', 'Allelic NF1 disorders include Watson syndrome and NFNS. Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742). NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382). 

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results from blood or saliva specimens alone may not distinguish between germline and acquired variants in this gene and additional testing may be appropriate.   ', '0', NULL),","The NF1 gene is associated with autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013), neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089) and Watson syndrome (MedGen UID: 107817).   NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).             Allelic NF1 disorders include Watson syndrome and NFNS. Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742). NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382). 

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results from blood or saliva specimens alone may not distinguish between germline and acquired variants in this gene and additional testing may be appropriate."
NF2,The NF2 gene is associated with autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).,"Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995).",,NO,,,"('NF2', 'The NF2 gene is associated with autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										', 'Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995).', '', '1', NULL),","The NF2 gene is associated with autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										  Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995)."
NTHL1 - Monoallelic,The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).,"NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).",,NO,,,"('NTHL1 - Monoallelic', 'The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).', 'NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).', '', '0', NULL),","The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).  NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593)."
NTHL1 - Biallelic,The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).,"NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).",,NO,,,"('NTHL1 - Biallelic', 'The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).', 'NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).', '', '0', NULL),","The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).  NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593)."
PALB2,"The PALB2 gene is associated with autosomal dominant predisposition to breast, pancreatic (PMID: 25099575, 31841383) and ovarian cancer (PMID: 30733081) in addition to autosomal recessive Fanconi anemia (MedGen UID: 372133). Studies have also suggested PALB2 may be associated with autosomal dominant predisposition to prostate (PMID: 17287723), male breast cancer (PMID: 31841383) and colorectal cancer (PMID: 29478780). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.","The lifetime risk of breast cancer in females with a pathogenic PALB2 variant is 33-58% (PMID: 25099575, 33471974). There is also a 2-5% risk of pancreatic cancer (PMID: 21285249, 31841383) and a 3-5% risk of ovarian cancer (PMID: 31841383, 28888541, Kurian et al. 2017).","Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).",YES,,,"('PALB2', 'The PALB2 gene is associated with autosomal dominant predisposition to breast, pancreatic (PMID: 25099575, 31841383) and ovarian cancer (PMID: 30733081) in addition to autosomal recessive Fanconi anemia (MedGen UID: 372133). Studies have also suggested PALB2 may be associated with autosomal dominant predisposition to prostate (PMID: 17287723), male breast cancer (PMID: 31841383) and colorectal cancer (PMID: 29478780). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.', 'The lifetime risk of breast cancer in females with a pathogenic PALB2 variant is 33-58% (PMID: 25099575, 33471974). There is also a 2-5% risk of pancreatic cancer (PMID: 21285249, 31841383) and a 3-5% risk of ovarian cancer (PMID: 31841383, 28888541, Kurian et al. 2017).', 'Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).', '0', NULL),","The PALB2 gene is associated with autosomal dominant predisposition to breast, pancreatic (PMID: 25099575, 31841383) and ovarian cancer (PMID: 30733081) in addition to autosomal recessive Fanconi anemia (MedGen UID: 372133). Studies have also suggested PALB2 may be associated with autosomal dominant predisposition to prostate (PMID: 17287723), male breast cancer (PMID: 31841383) and colorectal cancer (PMID: 29478780). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic PALB2 variant is 33-58% (PMID: 25099575, 33471974). There is also a 2-5% risk of pancreatic cancer (PMID: 21285249, 31841383) and a 3-5% risk of ovarian cancer (PMID: 31841383, 28888541, Kurian et al. 2017).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516)."
PDGFRA,The PDGFRA gene is associated with autosomal dominant GIST-plus syndrome (MedGen UID: 357402).,"GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943).",,NO,,,"('PDGFRA', 'The PDGFRA gene is associated with autosomal dominant GIST-plus syndrome (MedGen UID: 357402).', 'GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943).
', '', '1', NULL),","The PDGFRA gene is associated with autosomal dominant GIST-plus syndrome (MedGen UID: 357402).  GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943)."
PHOX2B,"The PHOX2B gene is associated with autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.","CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).",,NO,,,"('PHOX2B', 'The PHOX2B gene is associated with autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											', 'CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).                                                                                       ', '', '0', NULL),","The PHOX2B gene is associated with autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											  CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma)."
PMS2,"The PMS2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 325005) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).","PMS2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract and possibly prostate. Estimated lifetime cancer risks appear to be lower than those seen with other mismatch repair genes and include a 9-20% risk for colorectal cancer and up to a 3.7% risk of urinary tract cancer. Affected females also have an increased risk of uterine/endometrial cancer (13–26%) and ovarian cancer (3%) (PMID: 18602922, 30161022, 31204389, 28754778, 26657901, 31337882).","CMMR-D is a cancer syndrome characterized by childhood cancers, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).",YES,,,"('PMS2', 'The PMS2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 325005) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).', 'PMS2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract and possibly prostate. Estimated lifetime cancer risks appear to be lower than those seen with other mismatch repair genes and include a 9-20% risk for colorectal cancer and up to a 3.7% risk of urinary tract cancer. Affected females also have an increased risk of uterine/endometrial cancer (13–26%) and ovarian cancer (3%) (PMID: 18602922, 30161022, 31204389, 28754778, 26657901, 31337882).', 'CMMR-D is a cancer syndrome characterized by childhood cancers, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).', '0', NULL),","The PMS2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 325005) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  PMS2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract and possibly prostate. Estimated lifetime cancer risks appear to be lower than those seen with other mismatch repair genes and include a 9-20% risk for colorectal cancer and up to a 3.7% risk of urinary tract cancer. Affected females also have an increased risk of uterine/endometrial cancer (13–26%) and ovarian cancer (3%) (PMID: 18602922, 30161022, 31204389, 28754778, 26657901, 31337882).  CMMR-D is a cancer syndrome characterized by childhood cancers, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897)."
POLD1,"The POLD1 gene is associated with autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445) and autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). There is also preliminary evidence supporting a correlation with autosomal dominant predisposition to endometrial cancer (PMID: 23263490, 26133394), autosomal recessive combined immunodeficiency syndrome (PMID: 31629014) and autosomal recessive non-syndromic deafness (PMID: 31944473). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608).",,NO,,,"('POLD1', 'The POLD1 gene is associated with autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445) and autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). There is also preliminary evidence supporting a correlation with autosomal dominant predisposition to endometrial cancer (PMID: 23263490, 26133394), autosomal recessive combined immunodeficiency syndrome (PMID: 31629014) and autosomal recessive non-syndromic deafness (PMID: 31944473). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608).', '', '1', NULL),","The POLD1 gene is associated with autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445) and autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). There is also preliminary evidence supporting a correlation with autosomal dominant predisposition to endometrial cancer (PMID: 23263490, 26133394), autosomal recessive combined immunodeficiency syndrome (PMID: 31629014) and autosomal recessive non-syndromic deafness (PMID: 31944473). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608)."
POLE,"The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374) and autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).","Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).","FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001).",NO,,,"('POLE', 'The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374) and autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).', 'Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).', 'FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001).', '0', NULL),","The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374) and autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).  Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).  FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001)."
POT1,The POT1 gene is associated with autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).,"POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245.",,NO,,,"('POT1', 'The POT1 gene is associated with autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).', 'POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245.', '', '0', NULL),","The POT1 gene is associated with autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).  POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245."
PRKAR1A,The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: 388559) and acrodysostosis (MedGen UID: 477858).,"CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary.",,NO,,,"('PRKAR1A', 'The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: 388559) and acrodysostosis (MedGen UID: 477858).			', 'CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing''s syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary.', '', '0', NULL),","The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: 388559) and acrodysostosis (MedGen UID: 477858).			  CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary."
PRSS1,The PRSS1 gene is associated with autosomal dominant hereditary pancreatitis (Medgen UID: 116056).,"Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor pancreatic cancer. Other associated symptoms include exocrine pancreatic insufficiency and diabetes mellitus (PMID: 19453252, 18755888, 12120221, 21844754).",,NO,,,"('PRSS1', 'The PRSS1 gene is associated with autosomal dominant hereditary pancreatitis (Medgen UID: 116056).', 'Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor pancreatic cancer. Other associated symptoms include exocrine pancreatic insufficiency and diabetes mellitus (PMID: 19453252, 18755888, 12120221, 21844754).', '', '0', NULL),","The PRSS1 gene is associated with autosomal dominant hereditary pancreatitis (Medgen UID: 116056).  Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor pancreatic cancer. Other associated symptoms include exocrine pancreatic insufficiency and diabetes mellitus (PMID: 19453252, 18755888, 12120221, 21844754)."
PTCH1,"The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274).",,NO,,,"('PTCH1', 'The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274).', '', '0', NULL),","The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274)."
PTEN,"The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).","PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137).",,YES,Hide Thyroid,"[""Thyroid""]","('PTEN', 'The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).', 'PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137).                                ', '', '0', '[""Thyroid""]'),","The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).  PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137)."
RAD50,The RAD50 gene is associated with autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).,"NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.","Studies had previously suggested that females with a pathogenic variant in RAD50 may have autosomal dominant predisposition to breast cancer (PMID: 21356067, 24894818); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).",NO,,,"('RAD50', 'The RAD50 gene is associated with autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).', 'NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.', 'Studies had previously suggested that females with a pathogenic variant in RAD50 may have autosomal dominant predisposition to breast cancer (PMID: 21356067, 24894818); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).', '1', NULL),","The RAD50 gene is associated with autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).  NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.  Studies had previously suggested that females with a pathogenic variant in RAD50 may have autosomal dominant predisposition to breast cancer (PMID: 21356067, 24894818); however, more recent data have not supported this assertion (PMID: 33471974, 33471991)."
RAD51C,"The RAD51C gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 462009). Studies have also suggested RAD51C may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846) and autosomal recessive Fanconi anemia (PMID: 20400963). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","The lifetime risks among females with a pathogenic RAD51C variant are estimated to be 5-11% for ovarian cancer (PMID: 30733081, 32107557, Kurian et al. 2017) and 21-25% for breast cancer (PMID: 33471991, 32107557, 32091585).",,YES,,,"('RAD51C', 'The RAD51C gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 462009). Studies have also suggested RAD51C may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846) and autosomal recessive Fanconi anemia (PMID: 20400963). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'The lifetime risks among females with a pathogenic RAD51C variant are estimated to be 5-11% for ovarian cancer (PMID: 30733081, 32107557, Kurian et al. 2017) and 21-25% for breast cancer (PMID: 33471991, 32107557, 32091585).', '', '0', NULL),","The RAD51C gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 462009). Studies have also suggested RAD51C may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846) and autosomal recessive Fanconi anemia (PMID: 20400963). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risks among females with a pathogenic RAD51C variant are estimated to be 5-11% for ovarian cancer (PMID: 30733081, 32107557, Kurian et al. 2017) and 21-25% for breast cancer (PMID: 33471991, 32107557, 32091585)."
RAD51D,"The RAD51D gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 481975). Studies have also suggested RAD51D may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846). The data, however, are preliminary and  insufficient to make a determination regarding this relationship.","The lifetime risks among females with a pathogenic RAD51D variant are estimated to be 8-13% for ovarian cancer (PMID: 30733081, 32107557) and 20-31% for breast cancer (PMID: 28418444, 32091585, 33471974).",,YES,,,"('RAD51D', 'The RAD51D gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 481975). Studies have also suggested RAD51D may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846). The data, however, are preliminary and  insufficient to make a determination regarding this relationship. ', 'The lifetime risks among females with a pathogenic RAD51D variant are estimated to be 8-13% for ovarian cancer (PMID: 30733081, 32107557) and 20-31% for breast cancer (PMID: 28418444, 32091585, 33471974).', '', '1', NULL),","The RAD51D gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 481975). Studies have also suggested RAD51D may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846). The data, however, are preliminary and  insufficient to make a determination regarding this relationship.   The lifetime risks among females with a pathogenic RAD51D variant are estimated to be 8-13% for ovarian cancer (PMID: 30733081, 32107557) and 20-31% for breast cancer (PMID: 28418444, 32091585, 33471974)."
RB1,"The RB1 gene is associated with autosomal dominant retinoblastoma (MedGen UID: 20552). There is also evidence suggesting RB1 is associated with predisposition to several cancer types in retinoblastoma survivors (PMID: 14996857, 22355046).","Retinoblastoma (Rb) is a rare, early-childhood cancer that forms in the retina of the eye. The majority of individuals with hereditary Rb develop multiple tumors in both eyes with nearly complete penetrance; however, unilateral disease is not uncommon. A small subset of cases show a reduced penetrance phenotype with variable expressivity (PMID: 32422154). Affected individuals also appear to have an increased risk of developing secondary extra-ocular primary cancers including pinealoma, osteosarcoma, soft tissue sarcomas, and melanoma. The specific risk of these extra-ocular cancers is unknown, but is significantly increased among those who have received prior external beam radiation therapy (PMID: 32422154).",,NO,,,"('RB1', 'The RB1 gene is associated with autosomal dominant retinoblastoma (MedGen UID: 20552). There is also evidence suggesting RB1 is associated with predisposition to several cancer types in retinoblastoma survivors (PMID: 14996857, 22355046).', 'Retinoblastoma (Rb) is a rare, early-childhood cancer that forms in the retina of the eye. The majority of individuals with hereditary Rb develop multiple tumors in both eyes with nearly complete penetrance; however, unilateral disease is not uncommon. A small subset of cases show a reduced penetrance phenotype with variable expressivity (PMID: 32422154). Affected individuals also appear to have an increased risk of developing secondary extra-ocular primary cancers including pinealoma, osteosarcoma, soft tissue sarcomas, and melanoma. The specific risk of these extra-ocular cancers is unknown, but is significantly increased among those who have received prior external beam radiation therapy (PMID: 32422154).', '', '1', NULL),","The RB1 gene is associated with autosomal dominant retinoblastoma (MedGen UID: 20552). There is also evidence suggesting RB1 is associated with predisposition to several cancer types in retinoblastoma survivors (PMID: 14996857, 22355046).  Retinoblastoma (Rb) is a rare, early-childhood cancer that forms in the retina of the eye. The majority of individuals with hereditary Rb develop multiple tumors in both eyes with nearly complete penetrance; however, unilateral disease is not uncommon. A small subset of cases show a reduced penetrance phenotype with variable expressivity (PMID: 32422154). Affected individuals also appear to have an increased risk of developing secondary extra-ocular primary cancers including pinealoma, osteosarcoma, soft tissue sarcomas, and melanoma. The specific risk of these extra-ocular cancers is unknown, but is significantly increased among those who have received prior external beam radiation therapy (PMID: 32422154)."
RECQL,"The RECQL gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to breast cancer (PMID: 28724667, 30610487).",,,NO,,,"('RECQL', 'The RECQL gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to breast cancer (PMID: 28724667, 30610487).', '', '', '0', NULL),","The RECQL gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to breast cancer (PMID: 28724667, 30610487)."
RECQL4 - Monoallelic,"The RECQL4 gene is associated with autosomal recessive Rothmund-Thomson syndrome (RTS) (MedGen UID: 10819), RAPADILINO syndrome (MedGen UID: 336602) and Baller-Gerold syndrome (BGS) (MedGen UID: 120532).","RECQL4-related disorders include RTS, RAPADILINO syndrome and BGS. These rare disorders are characterized by epithelial features (poikiloderma, except in RAPADILINO), congenital skeletal malformations, and occasionally abnormalities of the teeth and nails. Coronal craniosynostosis is a feature unique only to BGS. RECQL4-related disorders are also associated with an increased susceptibility to specific cancers including osteosarcoma, hematological malignancy, and skin cancer (PMID: 20503338, 24960165, 11471165).",,NO,,,"('RECQL4 - Monoallelic', 'The RECQL4 gene is associated with autosomal recessive Rothmund-Thomson syndrome (RTS) (MedGen UID: 10819), RAPADILINO syndrome (MedGen UID: 336602) and Baller-Gerold syndrome (BGS) (MedGen UID: 120532).', 'RECQL4-related disorders include RTS, RAPADILINO syndrome and BGS. These rare disorders are characterized by epithelial features (poikiloderma, except in RAPADILINO), congenital skeletal malformations, and occasionally abnormalities of the teeth and nails. Coronal craniosynostosis is a feature unique only to BGS. RECQL4-related disorders are also associated with an increased susceptibility to specific cancers including osteosarcoma, hematological malignancy, and skin cancer (PMID: 20503338, 24960165, 11471165).', '', '0', NULL),","The RECQL4 gene is associated with autosomal recessive Rothmund-Thomson syndrome (RTS) (MedGen UID: 10819), RAPADILINO syndrome (MedGen UID: 336602) and Baller-Gerold syndrome (BGS) (MedGen UID: 120532).  RECQL4-related disorders include RTS, RAPADILINO syndrome and BGS. These rare disorders are characterized by epithelial features (poikiloderma, except in RAPADILINO), congenital skeletal malformations, and occasionally abnormalities of the teeth and nails. Coronal craniosynostosis is a feature unique only to BGS. RECQL4-related disorders are also associated with an increased susceptibility to specific cancers including osteosarcoma, hematological malignancy, and skin cancer (PMID: 20503338, 24960165, 11471165)."
RET,The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).,"Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984).",,NO,,,"('RET', 'The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).', 'Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984).', '', '0', NULL),","The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984)."
RINT1,"The RINT1 gene is associated with autosomal recessive Infantile liver failure syndrome (MedGen UID: 1684678). There is also preliminary evidence supporting a correlation with breast cancer (PMID: 25050558, 33099839). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","Infantile liver failure syndrome is characterized by episodic acute liver failure usually triggered by an intercurrent illness. The first event typically occurs in early childhood with episodic liver dysfunction, hyperammonemia and coagulopathy. With supportive treatment, the episodes resolve, though liver function may not normalize entirely (PMID: 31204009). Accumulated liver injury in the form of steatosis, bridging fibrosis, and increased Kupffer cells, caused at least one child to undergo liver transplant. Laboratory findings include elevated liver enzymes, total and direct hyperbilirubinemia, with increased prothrombin time and INRs (PMID: 31204009). Additional features of RALF include short stature and vertebral anomalies, with platyspondyly, hypoplastic, beaked and/or irregular vertebrae. Irregular femoral head epiphyses have also been described. Though only a few affected individuals have been reported to date, thus far all have had normal development and cognitive function (PMID: 31204009).",,NO,,,"('RINT1', 'The RINT1 gene is associated with autosomal recessive Infantile liver failure syndrome (MedGen UID: 1684678). There is also preliminary evidence supporting a correlation with breast cancer (PMID: 25050558, 33099839). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'Infantile liver failure syndrome is characterized by episodic acute liver failure usually triggered by an intercurrent illness. The first event typically occurs in early childhood with episodic liver dysfunction, hyperammonemia and coagulopathy. With supportive treatment, the episodes resolve, though liver function may not normalize entirely (PMID: 31204009). Accumulated liver injury in the form of steatosis, bridging fibrosis, and increased Kupffer cells, caused at least one child to undergo liver transplant. Laboratory findings include elevated liver enzymes, total and direct hyperbilirubinemia, with increased prothrombin time and INRs (PMID: 31204009). Additional features of RALF include short stature and vertebral anomalies, with platyspondyly, hypoplastic, beaked and/or irregular vertebrae. Irregular femoral head epiphyses have also been described. Though only a few affected individuals have been reported to date, thus far all have had normal development and cognitive function (PMID: 31204009).', '', '0', NULL),","The RINT1 gene is associated with autosomal recessive Infantile liver failure syndrome (MedGen UID: 1684678). There is also preliminary evidence supporting a correlation with breast cancer (PMID: 25050558, 33099839). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Infantile liver failure syndrome is characterized by episodic acute liver failure usually triggered by an intercurrent illness. The first event typically occurs in early childhood with episodic liver dysfunction, hyperammonemia and coagulopathy. With supportive treatment, the episodes resolve, though liver function may not normalize entirely (PMID: 31204009). Accumulated liver injury in the form of steatosis, bridging fibrosis, and increased Kupffer cells, caused at least one child to undergo liver transplant. Laboratory findings include elevated liver enzymes, total and direct hyperbilirubinemia, with increased prothrombin time and INRs (PMID: 31204009). Additional features of RALF include short stature and vertebral anomalies, with platyspondyly, hypoplastic, beaked and/or irregular vertebrae. Irregular femoral head epiphyses have also been described. Though only a few affected individuals have been reported to date, thus far all have had normal development and cognitive function (PMID: 31204009)."
RNF43,"The RNF43 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 31243857).",,,NO,,,"('RNF43', 'The RNF43 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 31243857).', '', '', '0', NULL),","The RNF43 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 31243857)."
RPS20,"The RPS20 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant hereditary nonpolyposis colorectal cancer (HNPCC) (PMID: 24941021).",,,NO,,,"('RPS20', 'The RPS20 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant hereditary nonpolyposis colorectal cancer (HNPCC) (PMID: 24941021).', '', '', '0', NULL),","The RPS20 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant hereditary nonpolyposis colorectal cancer (HNPCC) (PMID: 24941021)."
RUNX1,The RUNX1 gene is associated with autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).,"Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate.",,NO,,,"('RUNX1', 'The RUNX1 gene is associated with autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).', 'Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate.', '', '0', NULL),","The RUNX1 gene is associated with autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).  Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate."
SDHA,"The SDHA gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 481622), gastrointestinal stromal tumors (GIST) (PMID: 20301715), and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHA may also be associated with autosomal dominant predisposition to renal cancer (PMID: 26722403) and pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding these relationships.","SDHA-associated PGL-PCC syndrome due to loss-of-function (LOF) variants is characterized by an increased risk of developing PGL and PCC. Germline LOF SDHA variants have also been identified in individuals and families with GIST (PMID: 21505157, 22974104, 23060355) and Carney-Stratakis syndrome, which is associated with both PGL and GIST. The lifetime risk to develop a SDHA-related tumor is estimated to be 1-10% (PMID: 29177515, 29978154, 30201732); however, the risk of malignant transformation is unclear. While the SDHA gene is associated with autosomal dominant mitochondrial complex II deficiency, LOF variants in this gene have not been observed in individuals with this condition.","Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised.",NO,,,"('SDHA', 'The SDHA gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 481622), gastrointestinal stromal tumors (GIST) (PMID: 20301715), and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHA may also be associated with autosomal dominant predisposition to renal cancer (PMID: 26722403) and pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding these relationships.', 'SDHA-associated PGL-PCC syndrome due to loss-of-function (LOF) variants is characterized by an increased risk of developing PGL and PCC. Germline LOF SDHA variants have also been identified in individuals and families with GIST (PMID: 21505157, 22974104, 23060355) and Carney-Stratakis syndrome, which is associated with both PGL and GIST. The lifetime risk to develop a SDHA-related tumor is estimated to be 1-10% (PMID: 29177515, 29978154, 30201732); however, the risk of malignant transformation is unclear. While the SDHA gene is associated with autosomal dominant mitochondrial complex II deficiency, LOF variants in this gene have not been observed in individuals with this condition.', 'Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised.', '0', NULL),","The SDHA gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 481622), gastrointestinal stromal tumors (GIST) (PMID: 20301715), and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHA may also be associated with autosomal dominant predisposition to renal cancer (PMID: 26722403) and pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  SDHA-associated PGL-PCC syndrome due to loss-of-function (LOF) variants is characterized by an increased risk of developing PGL and PCC. Germline LOF SDHA variants have also been identified in individuals and families with GIST (PMID: 21505157, 22974104, 23060355) and Carney-Stratakis syndrome, which is associated with both PGL and GIST. The lifetime risk to develop a SDHA-related tumor is estimated to be 1-10% (PMID: 29177515, 29978154, 30201732); however, the risk of malignant transformation is unclear. While the SDHA gene is associated with autosomal dominant mitochondrial complex II deficiency, LOF variants in this gene have not been observed in individuals with this condition.  Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised."
SDHAF2,The SDHAF2 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 357076).,"Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGLs and PCCs. Pathogenic SDHAF2 variants predispose individuals to multiple head and neck paragangliomas, especially at early ages, although the lifetime risk of developing these tumors is unclear (PMID: 21224366, 20071235, 22241717). While the SDHAF2 gene follows traditional Mendelian inheritance, there is evidence suggesting a parent-of-origin effect; it appears that the risk of disease may be limited to paternally inherited pathogenic variants (PMID: 28099933, 21224366).",,NO,,,"('SDHAF2', 'The SDHAF2 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 357076).', 'Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGLs and PCCs. Pathogenic SDHAF2 variants predispose individuals to multiple head and neck paragangliomas, especially at early ages, although the lifetime risk of developing these tumors is unclear (PMID: 21224366, 20071235, 22241717). While the SDHAF2 gene follows traditional Mendelian inheritance, there is evidence suggesting a parent-of-origin effect; it appears that the risk of disease may be limited to paternally inherited pathogenic variants (PMID: 28099933, 21224366).', '', '0', NULL),","The SDHAF2 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 357076).  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGLs and PCCs. Pathogenic SDHAF2 variants predispose individuals to multiple head and neck paragangliomas, especially at early ages, although the lifetime risk of developing these tumors is unclear (PMID: 21224366, 20071235, 22241717). While the SDHAF2 gene follows traditional Mendelian inheritance, there is evidence suggesting a parent-of-origin effect; it appears that the risk of disease may be limited to paternally inherited pathogenic variants (PMID: 28099933, 21224366)."
SDHB,"The SDHB gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 349380), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049), renal cancer (PMID: 29386252, 23083876) and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHB may also be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGL and PCC. SDHB is also associated with autosomal dominant predisposition to renal cancer (PMID: 18728283, 23083876), GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). The lifetime risk of developing PGL and/or PCC is 22-49% (PMID: 28374168, 29386252, 30201732). PGL, PCC and GIST are typically benign but have a risk of malignant transformation; lifetime cancer risks are not clear (PMID: 30536464, 29386252). There is approximately a 5% risk of kidney cancer to age 60 (PMID: 29386252, 23083876).","Mitochondrial complex II deficiency is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy. Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy. The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 22972948, 23322652).",NO,,,"('SDHB', 'The SDHB gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 349380), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049), renal cancer (PMID: 29386252, 23083876) and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHB may also be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGL and PCC. SDHB is also associated with autosomal dominant predisposition to renal cancer (PMID: 18728283, 23083876), GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). The lifetime risk of developing PGL and/or PCC is 22-49% (PMID: 28374168, 29386252, 30201732). PGL, PCC and GIST are typically benign but have a risk of malignant transformation; lifetime cancer risks are not clear (PMID: 30536464, 29386252). There is approximately a 5% risk of kidney cancer to age 60 (PMID: 29386252, 23083876).', 'Mitochondrial complex II deficiency is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy. Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy. The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 22972948, 23322652).', '0', NULL),","The SDHB gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 349380), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049), renal cancer (PMID: 29386252, 23083876) and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHB may also be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGL and PCC. SDHB is also associated with autosomal dominant predisposition to renal cancer (PMID: 18728283, 23083876), GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). The lifetime risk of developing PGL and/or PCC is 22-49% (PMID: 28374168, 29386252, 30201732). PGL, PCC and GIST are typically benign but have a risk of malignant transformation; lifetime cancer risks are not clear (PMID: 30536464, 29386252). There is approximately a 5% risk of kidney cancer to age 60 (PMID: 29386252, 23083876).  Mitochondrial complex II deficiency is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy. Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy. The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 22972948, 23322652)."
SDHC,"The SDHC gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 340200), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and renal cancer (PMID: 23083876).  Studies also suggest SDHC may be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and available evidence is insufficient to make a determination regarding this relationship.","SDHC-associated hereditary PGL-PCC syndrome is associated with an 8-25% risk of developing PGL and/or PCC that are typically benign (PMID: 30201732, 29386252). Affected individuals will more often develop PGL in the head and neck. SDHC is also associated with autosomal dominant predisposition to to renal cancer (PMID: 23083876), GIST and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967, 21173220). PGL, PCC and GIST may become malignant; however, lifetime cancer risks are not clear. The lifetime risk of renal cancer is not established.",,NO,,,"('SDHC', 'The SDHC gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 340200), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and renal cancer (PMID: 23083876).  Studies also suggest SDHC may be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and available evidence is insufficient to make a determination regarding this relationship.', 'SDHC-associated hereditary PGL-PCC syndrome is associated with an 8-25% risk of developing PGL and/or PCC that are typically benign (PMID: 30201732, 29386252). Affected individuals will more often develop PGL in the head and neck. SDHC is also associated with autosomal dominant predisposition to to renal cancer (PMID: 23083876), GIST and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967, 21173220). PGL, PCC and GIST may become malignant; however, lifetime cancer risks are not clear. The lifetime risk of renal cancer is not established.', '', '0', NULL),","The SDHC gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 340200), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and renal cancer (PMID: 23083876).  Studies also suggest SDHC may be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and available evidence is insufficient to make a determination regarding this relationship.  SDHC-associated hereditary PGL-PCC syndrome is associated with an 8-25% risk of developing PGL and/or PCC that are typically benign (PMID: 30201732, 29386252). Affected individuals will more often develop PGL in the head and neck. SDHC is also associated with autosomal dominant predisposition to to renal cancer (PMID: 23083876), GIST and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967, 21173220). PGL, PCC and GIST may become malignant; however, lifetime cancer risks are not clear. The lifetime risk of renal cancer is not established."
SDHD,"The SDHD gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 358258) and gastrointestinal stromal tumors (GIST) (PMID: 24886695). Studies suggest SDHD is also associated with autosomal dominant predisposition to renal cancer (PMID: 19802898, 23083876) and pituitary adenomas (PMID: 26259135), as well as autosomal recessive mitochondrial complex II deficiency (PMID: 24367056; 26008905). The data, however, are preliminary and available evidence is insufficient to make a determination regarding these relationships.","Individuals with SDHD-associated hereditary PGL-PCC syndrome have a 43-70% risk of developing a PGL by age 60 (PMID: 29386252) and these tumors most often develop in the head and neck. SDHD is also associated with GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). SDHD-associated PGL, PCC and GIST have a risk of malignant transformation; however, lifetime risks are not clear. While both males and females can pass this variant on to their children, there is evidence suggesting that only those who inherit it from their father are at risk of developing SDHD-associated tumors (PMID: 25300370, 21937622, 19205158, 18211978).",,NO,,,"('SDHD', 'The SDHD gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 358258) and gastrointestinal stromal tumors (GIST) (PMID: 24886695). Studies suggest SDHD is also associated with autosomal dominant predisposition to renal cancer (PMID: 19802898, 23083876) and pituitary adenomas (PMID: 26259135), as well as autosomal recessive mitochondrial complex II deficiency (PMID: 24367056; 26008905). The data, however, are preliminary and available evidence is insufficient to make a determination regarding these relationships.', 'Individuals with SDHD-associated hereditary PGL-PCC syndrome have a 43-70% risk of developing a PGL by age 60 (PMID: 29386252) and these tumors most often develop in the head and neck. SDHD is also associated with GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). SDHD-associated PGL, PCC and GIST have a risk of malignant transformation; however, lifetime risks are not clear. While both males and females can pass this variant on to their children, there is evidence suggesting that only those who inherit it from their father are at risk of developing SDHD-associated tumors (PMID: 25300370, 21937622, 19205158, 18211978).', '', '0', NULL),","The SDHD gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 358258) and gastrointestinal stromal tumors (GIST) (PMID: 24886695). Studies suggest SDHD is also associated with autosomal dominant predisposition to renal cancer (PMID: 19802898, 23083876) and pituitary adenomas (PMID: 26259135), as well as autosomal recessive mitochondrial complex II deficiency (PMID: 24367056; 26008905). The data, however, are preliminary and available evidence is insufficient to make a determination regarding these relationships.  Individuals with SDHD-associated hereditary PGL-PCC syndrome have a 43-70% risk of developing a PGL by age 60 (PMID: 29386252) and these tumors most often develop in the head and neck. SDHD is also associated with GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). SDHD-associated PGL, PCC and GIST have a risk of malignant transformation; however, lifetime risks are not clear. While both males and females can pass this variant on to their children, there is evidence suggesting that only those who inherit it from their father are at risk of developing SDHD-associated tumors (PMID: 25300370, 21937622, 19205158, 18211978)."
SLX4,"The SLX4 gene is associated with autosomal recessive Fanconi anemia, type P (FA-P) (MedGen UID: 450103).","Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).",,NO,,,"('SLX4', 'The SLX4 gene is associated with autosomal recessive Fanconi anemia, type P (FA-P) (MedGen UID: 450103).', 'Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).', '', '0', NULL),","The SLX4 gene is associated with autosomal recessive Fanconi anemia, type P (FA-P) (MedGen UID: 450103).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516)."
SMAD4,"The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).","Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.","Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.",NO,,,"('SMAD4', 'The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).', 'Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias. ', 'Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.', '0', NULL),","The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).  Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.   Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT."
SMARCA4,"The SMARCA4 gene is associated with rhabdoid tumor predisposition syndrome, type 2, autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001) and Coffin-Siris syndrome (CSS) (MedGen UID: 766163).","Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays.",,NO,,,"('SMARCA4', 'The SMARCA4 gene is associated with rhabdoid tumor predisposition syndrome, type 2, autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001) and Coffin-Siris syndrome (CSS) (MedGen UID: 766163).', 'Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays.', '', '0', NULL),","The SMARCA4 gene is associated with rhabdoid tumor predisposition syndrome, type 2, autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001) and Coffin-Siris syndrome (CSS) (MedGen UID: 766163).  Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays."
SMARCB1,"The SMARCB1 gene is associated with autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892), schwannomatosis (MedGen UID: 234775) and Coffin-Siris syndrome (MedGen UID: 766162).","RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system. Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904). 

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 25168959, 25169878, 23929686).",,NO,,,"('SMARCB1', 'The SMARCB1 gene is associated with autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892), schwannomatosis (MedGen UID: 234775) and Coffin-Siris syndrome (MedGen UID: 766162).', 'RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system. Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904). 

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 25168959, 25169878, 23929686).', '', '0', NULL),","The SMARCB1 gene is associated with autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892), schwannomatosis (MedGen UID: 234775) and Coffin-Siris syndrome (MedGen UID: 766162).  RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system. Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904). 

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 25168959, 25169878, 23929686)."
SMARCE1,The SMARCE1 gene is associated with autosomal dominant familial meningioma (MedGen UID: 232281) and Coffin-Siris syndrome (MedGen UID: 934755).,"Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).

Coffin-Siris syndrome (CSS) is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 23929686, 27264197, 30499906, 25168959, 25169878, 23929686). While SMARCE1 is also associated with autosomal dominant CSS, to date, LOF variants in this gene have not been observed in individuals affected with CSS.",,NO,,,"('SMARCE1', 'The SMARCE1 gene is associated with autosomal dominant familial meningioma (MedGen UID: 232281) and Coffin-Siris syndrome (MedGen UID: 934755).', 'Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).

Coffin-Siris syndrome (CSS) is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 23929686, 27264197, 30499906, 25168959, 25169878, 23929686). While SMARCE1 is also associated with autosomal dominant CSS, to date, LOF variants in this gene have not been observed in individuals affected with CSS.', '', '0', NULL),","The SMARCE1 gene is associated with autosomal dominant familial meningioma (MedGen UID: 232281) and Coffin-Siris syndrome (MedGen UID: 934755).  Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).

Coffin-Siris syndrome (CSS) is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 23929686, 27264197, 30499906, 25168959, 25169878, 23929686). While SMARCE1 is also associated with autosomal dominant CSS, to date, LOF variants in this gene have not been observed in individuals affected with CSS."
SPINK1,The SPINK1 gene is associated with autosomal dominant predisposition to hereditary pancreatitis (MedGen UID: 116056).,"Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Pathogenic variants in SPINK1 are associated with increased susceptibility to chronic pancreatitis (PMID: 25206283, 24522117). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The phenotype of individuals with the same allelic variant may differ due to other genetic and environmental risk factors. Individuals with a pathogenic variant or increased risk variant identified in both CFTR and SPINK1 have been reported to have more than a 65-fold increased risk for pancreatitis (PMID: 11729110, 17003641, 17681820, 20977904). The clinical presentation, severity and prognosis depends on the specific variants identified along with additional environmental factors.",,NO,,,"('SPINK1', 'The SPINK1 gene is associated with autosomal dominant predisposition to hereditary pancreatitis (MedGen UID: 116056).', 'Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Pathogenic variants in SPINK1 are associated with increased susceptibility to chronic pancreatitis (PMID: 25206283, 24522117). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The phenotype of individuals with the same allelic variant may differ due to other genetic and environmental risk factors. Individuals with a pathogenic variant or increased risk variant identified in both CFTR and SPINK1 have been reported to have more than a 65-fold increased risk for pancreatitis (PMID: 11729110, 17003641, 17681820, 20977904). The clinical presentation, severity and prognosis depends on the specific variants identified along with additional environmental factors.', '', '0', NULL),","The SPINK1 gene is associated with autosomal dominant predisposition to hereditary pancreatitis (MedGen UID: 116056).  Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Pathogenic variants in SPINK1 are associated with increased susceptibility to chronic pancreatitis (PMID: 25206283, 24522117). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The phenotype of individuals with the same allelic variant may differ due to other genetic and environmental risk factors. Individuals with a pathogenic variant or increased risk variant identified in both CFTR and SPINK1 have been reported to have more than a 65-fold increased risk for pancreatitis (PMID: 11729110, 17003641, 17681820, 20977904). The clinical presentation, severity and prognosis depends on the specific variants identified along with additional environmental factors."
STK11,The STK11 gene is associated with autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).,"PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991).",,YES,Hide Colorectal,"[""Colorectal""]","('STK11', 'The STK11 gene is associated with autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).', 'PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991).', '', '0', '[""Colorectal""]'),","The STK11 gene is associated with autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).  PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991)."
SUFU,"The SUFU gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554), autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).","Pathogenic loss-of-function (LOF) SUFU variants are associated with BCNS. BCNS is an early-onset condition characterized by the development of multiple basal cell carcinomas, cardiac and ovarian fibromas, palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. SUFU-related BCNS is associated with up to a 33% risk of medulloblastoma (PMID: 29186568, 25403219, 33066274).

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic ""molar tooth sign"" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term ""Joubert syndrome and related disorders (JSRD)"" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition.",,NO,,,"('SUFU', 'The SUFU gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554), autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).', 'Pathogenic loss-of-function (LOF) SUFU variants are associated with BCNS. BCNS is an early-onset condition characterized by the development of multiple basal cell carcinomas, cardiac and ovarian fibromas, palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. SUFU-related BCNS is associated with up to a 33% risk of medulloblastoma (PMID: 29186568, 25403219, 33066274).

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic ""molar tooth sign"" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term ""Joubert syndrome and related disorders (JSRD)"" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition.', '', '1', NULL),","The SUFU gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554), autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).  Pathogenic loss-of-function (LOF) SUFU variants are associated with BCNS. BCNS is an early-onset condition characterized by the development of multiple basal cell carcinomas, cardiac and ovarian fibromas, palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. SUFU-related BCNS is associated with up to a 33% risk of medulloblastoma (PMID: 29186568, 25403219, 33066274).

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic ""molar tooth sign"" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term ""Joubert syndrome and related disorders (JSRD)"" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition."
TERC,The TERC gene is associated with autosomal dominant TERC-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 338831).,"DC is a telomere disorder characterized by abnormal skin pigmentation, nail dystrophy and oral leukoplakia. Affected individuals have a predisposition to progressive bone marrow failure, pulmonary fibrosis and cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). There is some evidence of genetic anticipation due to telomere shortening in which older generations present with adult-onset pulmonary fibrosis and subsequent generations present in childhood with bone marrow failure (PMID: 15098033).",,NO,,,"('TERC', 'The TERC gene is associated with autosomal dominant TERC-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 338831).', 'DC is a telomere disorder characterized by abnormal skin pigmentation, nail dystrophy and oral leukoplakia. Affected individuals have a predisposition to progressive bone marrow failure, pulmonary fibrosis and cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). There is some evidence of genetic anticipation due to telomere shortening in which older generations present with adult-onset pulmonary fibrosis and subsequent generations present in childhood with bone marrow failure (PMID: 15098033).', '', '0', NULL),","The TERC gene is associated with autosomal dominant TERC-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 338831).  DC is a telomere disorder characterized by abnormal skin pigmentation, nail dystrophy and oral leukoplakia. Affected individuals have a predisposition to progressive bone marrow failure, pulmonary fibrosis and cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). There is some evidence of genetic anticipation due to telomere shortening in which older generations present with adult-onset pulmonary fibrosis and subsequent generations present in childhood with bone marrow failure (PMID: 15098033)."
TERT,The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793,"Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual’s telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).",,NO,,,"('TERT', 'The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793', 'Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual’s telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).', '', '0', NULL),","The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual’s telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200)."
TMEM127,"The TMEM127 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 18419). There is also evidence suggesting TMEM127 is associated with autosomal dominant predisposition to renal cancer (PMID: 33051659, 28973655). The data, however, are preliminary and insufficient to make a determination regarding this relationship.","Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk to develop PGLs and PCCs. Most evidence suggests TMEM127 is associated with primarily PCC; however, cases of extra-adrenal PGLs have also been reported (PMID: 33051659). The risk of malignant transformation appears to be low (PMID: 24899893, 26347711, 20301715).",,NO,,,"('TMEM127', 'The TMEM127 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 18419). There is also evidence suggesting TMEM127 is associated with autosomal dominant predisposition to renal cancer (PMID: 33051659, 28973655). The data, however, are preliminary and insufficient to make a determination regarding this relationship.', 'Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk to develop PGLs and PCCs. Most evidence suggests TMEM127 is associated with primarily PCC; however, cases of extra-adrenal PGLs have also been reported (PMID: 33051659). The risk of malignant transformation appears to be low (PMID: 24899893, 26347711, 20301715).', '', '0', NULL),","The TMEM127 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 18419). There is also evidence suggesting TMEM127 is associated with autosomal dominant predisposition to renal cancer (PMID: 33051659, 28973655). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk to develop PGLs and PCCs. Most evidence suggests TMEM127 is associated with primarily PCC; however, cases of extra-adrenal PGLs have also been reported (PMID: 33051659). The risk of malignant transformation appears to be low (PMID: 24899893, 26347711, 20301715)."
TP53,The TP53 gene is associated with autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).,"LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate.",,YES,,,"('TP53', 'The TP53 gene is associated with autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).', 'LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate.', '', '0', NULL),","The TP53 gene is associated with autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).  LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate."
TRIM37 - Monoallelic,The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).,"Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854).",,NO,,,"('TRIM37 - Monoallelic', 'The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).', 'Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854).', '', '1', NULL),","The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).  Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854)."
TRIM37 - Biallelic,The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).,"Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854).",,NO,,,"('TRIM37 - Biallelic', 'The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).', 'Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854).', '', '1', NULL),","The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).  Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms’ tumor (PMID: 14757854)."
TSC1,The TSC1 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).,"TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).",,NO,,,"('TSC1', 'The TSC1 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).', 'TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).', '', '0', NULL),","The TSC1 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421)."
TSC2,The TSC2 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 348170).,"TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).",,NO,,,"('TSC2', 'The TSC2 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 348170).', 'TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).', '', '0', NULL),","The TSC2 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 348170).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421)."
VHL,"The VHL gene is associated with autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458) and autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).","von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).","Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342).",NO,,,"('VHL', 'The VHL gene is associated with autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458) and autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).', 'von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).', 'Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342).', '0', NULL),","The VHL gene is associated with autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458) and autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).  von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).  Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342)."
WRN - Monoallelic,The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).,"WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).",,NO,,,"('WRN - Monoallelic', 'The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).', 'WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).', '', '0', NULL),","The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).  WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204)."
WRN - Biallelic,The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).,"WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).",,NO,,,"('WRN - Biallelic', 'The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).', 'WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).', '', '0', NULL),","The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).  WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204)."
WT1,"The WT1 gene is associated with autosomal dominant Denys-Drash syndrome (MedGen UID: 181980), Wilms tumor predisposition syndrome (MedGen UID: 447509), WAGR syndrome (MedGen UID: 64512) and Frasier syndrome (MedGen UID: 215533).","WT1-related disorders are associated with an increased risk for Wilms tumor, a type of renal cancer, which typically presents in early childhood. WT1-related Wilms tumor may occur as an isolated finding or as part of a syndrome. Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).","Other WT1-related disorders include Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies, and Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364). Nephrotic syndrome has also been linked to pathogenic variants in WT1 (PMID: 25818337).",NO,,,"('WT1', 'The WT1 gene is associated with autosomal dominant Denys-Drash syndrome (MedGen UID: 181980), Wilms tumor predisposition syndrome (MedGen UID: 447509), WAGR syndrome (MedGen UID: 64512) and Frasier syndrome (MedGen UID: 215533).', 'WT1-related disorders are associated with an increased risk for Wilms tumor, a type of renal cancer, which typically presents in early childhood. WT1-related Wilms tumor may occur as an isolated finding or as part of a syndrome. Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).', 'Other WT1-related disorders include Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies, and Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364). Nephrotic syndrome has also been linked to pathogenic variants in WT1 (PMID: 25818337).', '0', NULL),","The WT1 gene is associated with autosomal dominant Denys-Drash syndrome (MedGen UID: 181980), Wilms tumor predisposition syndrome (MedGen UID: 447509), WAGR syndrome (MedGen UID: 64512) and Frasier syndrome (MedGen UID: 215533).  WT1-related disorders are associated with an increased risk for Wilms tumor, a type of renal cancer, which typically presents in early childhood. WT1-related Wilms tumor may occur as an isolated finding or as part of a syndrome. Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).  Other WT1-related disorders include Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies, and Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364). Nephrotic syndrome has also been linked to pathogenic variants in WT1 (PMID: 25818337)."
XRCC2,"The XRCC2 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22464251, 25452441) and autosomal recessive Fanconi anemia (PMID: 22232082).",,,NO,,,"('XRCC2', 'The XRCC2 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22464251, 25452441) and autosomal recessive Fanconi anemia (PMID: 22232082).', '', '', '0', NULL),","The XRCC2 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22464251, 25452441) and autosomal recessive Fanconi anemia (PMID: 22232082)."